CN114728945A - 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 - Google Patents
3,5-二取代吡唑化合物作为激酶抑制剂及其应用 Download PDFInfo
- Publication number
- CN114728945A CN114728945A CN202080062058.2A CN202080062058A CN114728945A CN 114728945 A CN114728945 A CN 114728945A CN 202080062058 A CN202080062058 A CN 202080062058A CN 114728945 A CN114728945 A CN 114728945A
- Authority
- CN
- China
- Prior art keywords
- amino
- pyrazol
- carbonitrile
- phenyl
- pyrazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3, 5-disubstituted pyrazole compounds Chemical class 0.000 title claims description 99
- 229940043355 kinase inhibitor Drugs 0.000 title description 13
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 201
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims abstract description 38
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims abstract description 38
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 201000011510 cancer Diseases 0.000 claims abstract description 19
- 230000005778 DNA damage Effects 0.000 claims abstract description 14
- 231100000277 DNA damage Toxicity 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 230000004543 DNA replication Effects 0.000 claims abstract description 9
- 230000004913 activation Effects 0.000 claims abstract description 9
- 208000035475 disorder Diseases 0.000 claims abstract description 8
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 7
- 230000006378 damage Effects 0.000 claims abstract description 7
- 208000014674 injury Diseases 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 91
- 150000002367 halogens Chemical class 0.000 claims description 70
- 229910052736 halogen Inorganic materials 0.000 claims description 69
- 229910052739 hydrogen Inorganic materials 0.000 claims description 69
- 239000001257 hydrogen Substances 0.000 claims description 69
- 125000001424 substituent group Chemical group 0.000 claims description 55
- 125000000623 heterocyclic group Chemical group 0.000 claims description 44
- 125000003545 alkoxy group Chemical group 0.000 claims description 42
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 35
- 150000002431 hydrogen Chemical class 0.000 claims description 31
- 150000003254 radicals Chemical class 0.000 claims description 25
- 239000002246 antineoplastic agent Substances 0.000 claims description 24
- 229920006395 saturated elastomer Polymers 0.000 claims description 24
- 229940002612 prodrug Drugs 0.000 claims description 22
- 239000000651 prodrug Substances 0.000 claims description 22
- 239000012453 solvate Substances 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- WDUWPWJMIJOMJP-AWEZNQCLSA-N COC1=C(C(=CC=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N WDUWPWJMIJOMJP-AWEZNQCLSA-N 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 12
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 10
- 229940041181 antineoplastic drug Drugs 0.000 claims description 10
- 229960001433 erlotinib Drugs 0.000 claims description 10
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 10
- 125000002757 morpholinyl group Chemical group 0.000 claims description 10
- 125000003386 piperidinyl group Chemical group 0.000 claims description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
- 229960004641 rituximab Drugs 0.000 claims description 10
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 10
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 10
- 125000002393 azetidinyl group Chemical group 0.000 claims description 9
- 125000004193 piperazinyl group Chemical group 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- LGTRDBJSXJJPOE-ZDUSSCGKSA-N BrC=1C(=NNC=1C1=C(C=CC=C1OC[C@@H]1CNCCC1)OC)NC=1N=CC(=NC=1)C#N Chemical compound BrC=1C(=NNC=1C1=C(C=CC=C1OC[C@@H]1CNCCC1)OC)NC=1N=CC(=NC=1)C#N LGTRDBJSXJJPOE-ZDUSSCGKSA-N 0.000 claims description 7
- WDUWPWJMIJOMJP-CQSZACIVSA-N COC1=C(C(=CC=C1)OC[C@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N WDUWPWJMIJOMJP-CQSZACIVSA-N 0.000 claims description 7
- 125000003368 amide group Chemical group 0.000 claims description 7
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 6
- YWNVVCTYBHYZHO-CQSZACIVSA-N 5-[[5-[2-methoxy-6-[[(2R)-thiomorpholin-2-yl]methoxy]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile Chemical compound COC1=C(C(=CC=C1)OC[C@H]1CNCCS1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N YWNVVCTYBHYZHO-CQSZACIVSA-N 0.000 claims description 6
- PXPIPORKGJNKQC-HNNXBMFYSA-N COC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=C(C(=NN1)NC=1N=CC(=NC=1)C#N)C Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=C(C(=NN1)NC=1N=CC(=NC=1)C#N)C PXPIPORKGJNKQC-HNNXBMFYSA-N 0.000 claims description 6
- BWWSWJFPGGQVJB-INIZCTEOSA-N COC1=C(C(=CC=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1C=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1C=CC(=NC=1)C#N BWWSWJFPGGQVJB-INIZCTEOSA-N 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 229960002450 ofatumumab Drugs 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- CHNKUSZOXKOOBN-HNNXBMFYSA-N C(C)OC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound C(C)OC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N CHNKUSZOXKOOBN-HNNXBMFYSA-N 0.000 claims description 5
- JHANVUWXNPIMLW-HNNXBMFYSA-N COC1=C(C(=CC(=C1)C)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC(=C1)C)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N JHANVUWXNPIMLW-HNNXBMFYSA-N 0.000 claims description 5
- WTTMXPAHIIHUBB-AWEZNQCLSA-N COC1=C(C(=CC=C1)OC[C@H]1NCCNC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@H]1NCCNC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N WTTMXPAHIIHUBB-AWEZNQCLSA-N 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229940022353 herceptin Drugs 0.000 claims description 5
- YWNVVCTYBHYZHO-AWEZNQCLSA-N 5-[[5-[2-methoxy-6-[[(2S)-thiomorpholin-2-yl]methoxy]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1CNCCS1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N YWNVVCTYBHYZHO-AWEZNQCLSA-N 0.000 claims description 4
- KMUJZCNHJBRSDC-INIZCTEOSA-N C(C)(C)OC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound C(C)(C)OC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N KMUJZCNHJBRSDC-INIZCTEOSA-N 0.000 claims description 4
- 125000006519 CCH3 Chemical group 0.000 claims description 4
- RDBHHDJOVGOAEQ-AWEZNQCLSA-N COC1=C(C(=CC=C1)NC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)NC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N RDBHHDJOVGOAEQ-AWEZNQCLSA-N 0.000 claims description 4
- DVMLTYCYOKXYPI-UHFFFAOYSA-N COC1=C(C(=CC=C1)OC1CCNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC1CCNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N DVMLTYCYOKXYPI-UHFFFAOYSA-N 0.000 claims description 4
- MWIQKZBKFMYHOZ-UHFFFAOYSA-N COC1=C(C(=CC=C1)OCC1CCNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OCC1CCNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N MWIQKZBKFMYHOZ-UHFFFAOYSA-N 0.000 claims description 4
- WQOKFSZKBOWIMF-ZDUSSCGKSA-N COC1=C(C(=CC=C1)OC[C@@H]1CNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1CNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N WQOKFSZKBOWIMF-ZDUSSCGKSA-N 0.000 claims description 4
- IYAWWTCXAHDNHV-AWEZNQCLSA-N COC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC1=CC=C(N=N1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC1=CC=C(N=N1)C#N IYAWWTCXAHDNHV-AWEZNQCLSA-N 0.000 claims description 4
- RUUNEFJWVLZBHY-AWEZNQCLSA-N COC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N RUUNEFJWVLZBHY-AWEZNQCLSA-N 0.000 claims description 4
- STYWMEXTXMBVSK-AWEZNQCLSA-N COC1=C(C(=CC=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC1=NC=C(N=C1)C Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC1=NC=C(N=C1)C STYWMEXTXMBVSK-AWEZNQCLSA-N 0.000 claims description 4
- DJOIHALLKPGFCG-LBPRGKRZSA-N COC1=C(C(=CC=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC1=NC=C(N=C1)C(F)(F)F Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC1=NC=C(N=C1)C(F)(F)F DJOIHALLKPGFCG-LBPRGKRZSA-N 0.000 claims description 4
- GPJXPJHKAWQTBE-CQSZACIVSA-N COC1=C(C(=CC=C1)OC[C@@H]1NCCOC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1NCCOC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N GPJXPJHKAWQTBE-CQSZACIVSA-N 0.000 claims description 4
- FKBRNDXIEDPFRF-HNNXBMFYSA-N COC1=C(C(=CC=C1)OC[C@H]1OCCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@H]1OCCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N FKBRNDXIEDPFRF-HNNXBMFYSA-N 0.000 claims description 4
- XDDHIUUJROZFTA-ZDUSSCGKSA-N ClC1=CC(=C(C(=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound ClC1=CC(=C(C(=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC XDDHIUUJROZFTA-ZDUSSCGKSA-N 0.000 claims description 4
- XDMMBQHYKCIVOE-AWEZNQCLSA-N ClC1=CC(=C(C(=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound ClC1=CC(=C(C(=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC XDMMBQHYKCIVOE-AWEZNQCLSA-N 0.000 claims description 4
- CZGNBPWUSZYFNK-ZDUSSCGKSA-N ClC=1C(=C(C(=CC=1)OC)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC[C@@H]1CNCCO1 Chemical compound ClC=1C(=C(C(=CC=1)OC)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC[C@@H]1CNCCO1 CZGNBPWUSZYFNK-ZDUSSCGKSA-N 0.000 claims description 4
- GSDFEWMVZJRPFI-ZDUSSCGKSA-N ClC=1C(=C(C(=CC=1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound ClC=1C(=C(C(=CC=1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC GSDFEWMVZJRPFI-ZDUSSCGKSA-N 0.000 claims description 4
- JCUILLSBCSHESX-ZDUSSCGKSA-N FC1=C(C(=CC(=C1)C)OC[C@@H]1CNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound FC1=C(C(=CC(=C1)C)OC[C@@H]1CNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N JCUILLSBCSHESX-ZDUSSCGKSA-N 0.000 claims description 4
- FMCMMECHJXENDQ-AWEZNQCLSA-N FC1=C(C(=CC(=C1)C)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound FC1=C(C(=CC(=C1)C)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N FMCMMECHJXENDQ-AWEZNQCLSA-N 0.000 claims description 4
- HXBALWOKODFDHE-ZDUSSCGKSA-N FC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound FC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N HXBALWOKODFDHE-ZDUSSCGKSA-N 0.000 claims description 4
- LOQIASQNBIKFEQ-AWEZNQCLSA-N FC1=CC(=C(C(=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound FC1=CC(=C(C(=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC LOQIASQNBIKFEQ-AWEZNQCLSA-N 0.000 claims description 4
- OXXJASNLBWYFCK-UHFFFAOYSA-N N1CC(C1)COC1=C(C(=CC=C1)F)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound N1CC(C1)COC1=C(C(=CC=C1)F)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N OXXJASNLBWYFCK-UHFFFAOYSA-N 0.000 claims description 4
- YFAVODKACSNJIE-ZDUSSCGKSA-N N1C[C@H](OCC1)COC1=C(C(=CC=C1)OC(F)(F)F)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound N1C[C@H](OCC1)COC1=C(C(=CC=C1)OC(F)(F)F)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N YFAVODKACSNJIE-ZDUSSCGKSA-N 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- PMSVVUSIPKHUMT-UHFFFAOYSA-N cyanopyrazine Chemical compound N#CC1=CN=CC=N1 PMSVVUSIPKHUMT-UHFFFAOYSA-N 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 238000011275 oncology therapy Methods 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims description 3
- LHRCSEJHBIGPCB-LBPRGKRZSA-N 5-[[5-[2-fluoro-6-[[(3S)-pyrrolidin-3-yl]methoxy]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile Chemical compound FC1=C(C(=CC=C1)OC[C@@H]1CNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N LHRCSEJHBIGPCB-LBPRGKRZSA-N 0.000 claims description 3
- AYLPPPFRLPQFAK-CQSZACIVSA-N 5-[[5-[4-bromo-2-methoxy-6-[[(2R)-thiomorpholin-2-yl]methoxy]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile Chemical compound BrC1=CC(=C(C(=C1)OC[C@H]1CNCCS1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC AYLPPPFRLPQFAK-CQSZACIVSA-N 0.000 claims description 3
- WKVIKPNJCCCVIQ-INIZCTEOSA-N 5-[[5-[4-ethyl-2-methoxy-6-[[(3S)-piperidin-3-yl]methoxy]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile Chemical compound C(C)C1=CC(=C(C(=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC WKVIKPNJCCCVIQ-INIZCTEOSA-N 0.000 claims description 3
- ZFZSFVOCHSBDDU-CQSZACIVSA-N 5-[[5-[4-fluoro-2-methoxy-6-[[(2R)-thiomorpholin-2-yl]methoxy]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile Chemical compound FC1=CC(=C(C(=C1)OC[C@H]1CNCCS1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC ZFZSFVOCHSBDDU-CQSZACIVSA-N 0.000 claims description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 3
- VBTUJTGLLREMNW-UHFFFAOYSA-N 5-fluoro-1-[[4-fluoro-3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]quinazoline-2,4-dione Chemical compound FC1=CC=C(CN2C(NC(=O)C3=C(F)C=CC=C32)=O)C=C1C(=O)N(CC1)CCN1C1=NC=CC=N1 VBTUJTGLLREMNW-UHFFFAOYSA-N 0.000 claims description 3
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- JILSWZZFTPOLQS-LBPRGKRZSA-N BrC1=CC(=C(C(=C1)OC[C@@H]1CNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound BrC1=CC(=C(C(=C1)OC[C@@H]1CNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC JILSWZZFTPOLQS-LBPRGKRZSA-N 0.000 claims description 3
- DNCRWAKCXCJEPM-LBPRGKRZSA-N BrC1=CC(=C(C(=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)F Chemical compound BrC1=CC(=C(C(=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)F DNCRWAKCXCJEPM-LBPRGKRZSA-N 0.000 claims description 3
- VSWMBWAGOKGZSZ-ZDUSSCGKSA-N BrC1=CC(=C(C(=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound BrC1=CC(=C(C(=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC VSWMBWAGOKGZSZ-ZDUSSCGKSA-N 0.000 claims description 3
- PPVZNBPJXWOSKO-ZDUSSCGKSA-N BrC1=CC(=C(C(=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)F Chemical compound BrC1=CC(=C(C(=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)F PPVZNBPJXWOSKO-ZDUSSCGKSA-N 0.000 claims description 3
- VJEAVTBKZLKREB-AWEZNQCLSA-N BrC1=CC(=C(C(=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound BrC1=CC(=C(C(=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC VJEAVTBKZLKREB-AWEZNQCLSA-N 0.000 claims description 3
- WOLMBNBUKWQZCR-CYBMUJFWSA-N BrC1=CC(=C(C(=C1)OC[C@@H]1NCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound BrC1=CC(=C(C(=C1)OC[C@@H]1NCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC WOLMBNBUKWQZCR-CYBMUJFWSA-N 0.000 claims description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- MMEFIYMJNJUMSJ-HNNXBMFYSA-N C(C)C=1N=CC(=NC=1)NC1=NNC(=C1)C1=C(C=CC=C1OC[C@@H]1CNCCC1)OC Chemical compound C(C)C=1N=CC(=NC=1)NC1=NNC(=C1)C1=C(C=CC=C1OC[C@@H]1CNCCC1)OC MMEFIYMJNJUMSJ-HNNXBMFYSA-N 0.000 claims description 3
- KMCONTHKHQENFO-AWEZNQCLSA-N CC1(C)[C@H](COC2=C(C3=CC(NC(N=C4)=CN=C4C#N)=NN3)C(OC)=CC(F)=C2)CNCC1 Chemical compound CC1(C)[C@H](COC2=C(C3=CC(NC(N=C4)=CN=C4C#N)=NN3)C(OC)=CC(F)=C2)CNCC1 KMCONTHKHQENFO-AWEZNQCLSA-N 0.000 claims description 3
- UWVMMGVSPCVUHR-HNNXBMFYSA-N CC1([C@@H](CNCC1)COC1=C(C(=CC=C1)OC)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)C Chemical compound CC1([C@@H](CNCC1)COC1=C(C(=CC=C1)OC)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)C UWVMMGVSPCVUHR-HNNXBMFYSA-N 0.000 claims description 3
- JRRXPMURABWTHL-ZDUSSCGKSA-N COC1=C(C(=CC(=C1)C(F)(F)F)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC(=C1)C(F)(F)F)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N JRRXPMURABWTHL-ZDUSSCGKSA-N 0.000 claims description 3
- XNMAZONHXLMMGL-AWEZNQCLSA-N COC1=C(C(=CC(=C1)C(F)(F)F)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC(=C1)C(F)(F)F)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N XNMAZONHXLMMGL-AWEZNQCLSA-N 0.000 claims description 3
- IEVYKXBTFHGTHN-AWEZNQCLSA-N COC1=C(C(=CC(=C1)C)OC[C@@H]1CNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC(=C1)C)OC[C@@H]1CNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N IEVYKXBTFHGTHN-AWEZNQCLSA-N 0.000 claims description 3
- AAABGYDQHZQDAY-HNNXBMFYSA-N COC1=C(C(=CC(=C1)C)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC(=C1)C)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N AAABGYDQHZQDAY-HNNXBMFYSA-N 0.000 claims description 3
- UEUUEAOGZUTIJS-CQSZACIVSA-N COC1=C(C(=CC(=C1)C)OC[C@@H]1NCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC(=C1)C)OC[C@@H]1NCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N UEUUEAOGZUTIJS-CQSZACIVSA-N 0.000 claims description 3
- YWVTXXOUSAFJJV-OAHLLOKOSA-N COC1=C(C(=CC(=C1)C)OC[C@H]1CNCCS1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC(=C1)C)OC[C@H]1CNCCS1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N YWVTXXOUSAFJJV-OAHLLOKOSA-N 0.000 claims description 3
- HVPMDYVUHDOXGQ-UHFFFAOYSA-N COC1=C(C(=CC=C1)CCN1CCNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)CCN1CCNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N HVPMDYVUHDOXGQ-UHFFFAOYSA-N 0.000 claims description 3
- JGAOWSYNSODRIP-HNNXBMFYSA-N COC1=C(C(=CC=C1)N(C[C@@H]1CNCCO1)C)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)N(C[C@@H]1CNCCO1)C)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N JGAOWSYNSODRIP-HNNXBMFYSA-N 0.000 claims description 3
- WAXNVNVTTYIUPO-HNNXBMFYSA-N COC1=C(C(=CC=C1)OC[C@@H]1CN(CCC1)C)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1CN(CCC1)C)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N WAXNVNVTTYIUPO-HNNXBMFYSA-N 0.000 claims description 3
- BHSZLDNCPRCBLI-HNNXBMFYSA-N COC1=C(C(=CC=C1)OC[C@@H]1CN(CCO1)C)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1CN(CCO1)C)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N BHSZLDNCPRCBLI-HNNXBMFYSA-N 0.000 claims description 3
- UHOUUFRATJYNJE-INIZCTEOSA-N COC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC1=NC=C(C#N)C=C1 Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC1=NC=C(C#N)C=C1 UHOUUFRATJYNJE-INIZCTEOSA-N 0.000 claims description 3
- URVIEDKYCYRQMP-HNNXBMFYSA-N COC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=C(C(=NC=1)C#N)C Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=C(C(=NC=1)C#N)C URVIEDKYCYRQMP-HNNXBMFYSA-N 0.000 claims description 3
- GHRXXIQRPFCDDM-AWEZNQCLSA-N COC1=C(C(=CC=C1)OC[C@@H]1COCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1COCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N GHRXXIQRPFCDDM-AWEZNQCLSA-N 0.000 claims description 3
- ZHUKMOYXBMUKPZ-CYBMUJFWSA-N COC1=C(C(=CC=C1)OC[C@@H]1NCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1NCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N ZHUKMOYXBMUKPZ-CYBMUJFWSA-N 0.000 claims description 3
- UYAMUMDKZKVGLB-CQSZACIVSA-N COC1=C(C(=CC=C1)OC[C@@H]1NCCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1NCCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N UYAMUMDKZKVGLB-CQSZACIVSA-N 0.000 claims description 3
- QHFINYPRCIFFIV-HNNXBMFYSA-N COC1=C(C(=CC=C1)OC[C@H]1N(CCNC1)C)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@H]1N(CCNC1)C)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N QHFINYPRCIFFIV-HNNXBMFYSA-N 0.000 claims description 3
- NOIWEKBHLPZMPA-HNNXBMFYSA-N COC1=C(C(=CC=C1C)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC=C1C)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N NOIWEKBHLPZMPA-HNNXBMFYSA-N 0.000 claims description 3
- ATSOSPZSNBZMTD-AWEZNQCLSA-N COC=1N=CC(=NC=1)NC1=NNC(=C1)C1=C(C=CC=C1OC[C@@H]1CNCCC1)OC Chemical compound COC=1N=CC(=NC=1)NC1=NNC(=C1)C1=C(C=CC=C1OC[C@@H]1CNCCC1)OC ATSOSPZSNBZMTD-AWEZNQCLSA-N 0.000 claims description 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 3
- AFCBVOIEXJPDOQ-ZDUSSCGKSA-N ClC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound ClC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N AFCBVOIEXJPDOQ-ZDUSSCGKSA-N 0.000 claims description 3
- SNDXIPMIVYWKMQ-LBPRGKRZSA-N ClC1=CC(=C(C(=C1)OC[C@@H]1CNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound ClC1=CC(=C(C(=C1)OC[C@@H]1CNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC SNDXIPMIVYWKMQ-LBPRGKRZSA-N 0.000 claims description 3
- ZRIBQKDJHLKVMZ-ZDUSSCGKSA-N ClC1=CC(=C(C(=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)F Chemical compound ClC1=CC(=C(C(=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)F ZRIBQKDJHLKVMZ-ZDUSSCGKSA-N 0.000 claims description 3
- NVPZTZMARYWGHU-CQSZACIVSA-N ClC1=CC(=C(C(=C1)OC[C@H]1CNCCS1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound ClC1=CC(=C(C(=C1)OC[C@H]1CNCCS1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC NVPZTZMARYWGHU-CQSZACIVSA-N 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 3
- BIPGSDBXPVJTJN-AWEZNQCLSA-N FC1=C(C(=CC(=C1)C)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound FC1=C(C(=CC(=C1)C)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N BIPGSDBXPVJTJN-AWEZNQCLSA-N 0.000 claims description 3
- IQWFNNVKHRHHEH-LBPRGKRZSA-N FC1=C(C(=CC(=C1)F)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound FC1=C(C(=CC(=C1)F)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N IQWFNNVKHRHHEH-LBPRGKRZSA-N 0.000 claims description 3
- ZEDIPRJIORXBQK-ZDUSSCGKSA-N FC1=C(C(=CC=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound FC1=C(C(=CC=C1)OC[C@@H]1CNCCO1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N ZEDIPRJIORXBQK-ZDUSSCGKSA-N 0.000 claims description 3
- LMEXCKFVXWFZHN-LBPRGKRZSA-N FC1=CC(=C(C(=C1)OC[C@@H]1CNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound FC1=CC(=C(C(=C1)OC[C@@H]1CNCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC LMEXCKFVXWFZHN-LBPRGKRZSA-N 0.000 claims description 3
- OITYUKDXBOWVBF-ZDUSSCGKSA-N FC1=CC(=C(C(=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound FC1=CC(=C(C(=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC OITYUKDXBOWVBF-ZDUSSCGKSA-N 0.000 claims description 3
- MOAGFGPLYCTRBQ-CYBMUJFWSA-N FC1=CC(=C(C(=C1)OC[C@@H]1NCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound FC1=CC(=C(C(=C1)OC[C@@H]1NCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC MOAGFGPLYCTRBQ-CYBMUJFWSA-N 0.000 claims description 3
- RRLYWAUFCUIWON-ZDUSSCGKSA-N FC=1C(=C(C(=CC=1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound FC=1C(=C(C(=CC=1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC RRLYWAUFCUIWON-ZDUSSCGKSA-N 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 3
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 3
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 3
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 3
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 3
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- AHCVNDPVHTXFAK-UHFFFAOYSA-N N1CC(C1)COC1=C(C(=CC(=C1)Br)OC)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound N1CC(C1)COC1=C(C(=CC(=C1)Br)OC)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N AHCVNDPVHTXFAK-UHFFFAOYSA-N 0.000 claims description 3
- YUQZQXATLQQABX-UHFFFAOYSA-N N1CC(C1)COC1=C(C(=CC(=C1)C)F)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound N1CC(C1)COC1=C(C(=CC(=C1)C)F)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N YUQZQXATLQQABX-UHFFFAOYSA-N 0.000 claims description 3
- FXLNDQFQLAWQFU-UHFFFAOYSA-N N1CC(C1)COC1=C(C(=CC(=C1)C)OC)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound N1CC(C1)COC1=C(C(=CC(=C1)C)OC)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N FXLNDQFQLAWQFU-UHFFFAOYSA-N 0.000 claims description 3
- UPATXSAYRCJILE-UHFFFAOYSA-N N1CC(C1)COC1=C(C(=CC(=C1)Cl)OC)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound N1CC(C1)COC1=C(C(=CC(=C1)Cl)OC)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N UPATXSAYRCJILE-UHFFFAOYSA-N 0.000 claims description 3
- OCAJDVATDXDKHL-UHFFFAOYSA-N N1CC(C1)COC1=C(C(=CC=C1)OC)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound N1CC(C1)COC1=C(C(=CC=C1)OC)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N OCAJDVATDXDKHL-UHFFFAOYSA-N 0.000 claims description 3
- FKYHFBNQMFOZHS-ZDUSSCGKSA-N OC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound OC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N FKYHFBNQMFOZHS-ZDUSSCGKSA-N 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims description 3
- 229960004176 aclarubicin Drugs 0.000 claims description 3
- 229960001686 afatinib Drugs 0.000 claims description 3
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 3
- 229960000548 alemtuzumab Drugs 0.000 claims description 3
- 229940120638 avastin Drugs 0.000 claims description 3
- 229960002756 azacitidine Drugs 0.000 claims description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 3
- 229960003094 belinostat Drugs 0.000 claims description 3
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims description 3
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002707 bendamustine Drugs 0.000 claims description 3
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- 229960003008 blinatumomab Drugs 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- 229940127093 camptothecin Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- 229960005395 cetuximab Drugs 0.000 claims description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 3
- 229960004630 chlorambucil Drugs 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 229960001338 colchicine Drugs 0.000 claims description 3
- 229960005061 crizotinib Drugs 0.000 claims description 3
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 229960002448 dasatinib Drugs 0.000 claims description 3
- 229960004497 dinutuximab Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- 229960005167 everolimus Drugs 0.000 claims description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 3
- 229960000390 fludarabine Drugs 0.000 claims description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- 229960002258 fulvestrant Drugs 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- 102000055277 human IL2 Human genes 0.000 claims description 3
- 229960001101 ifosfamide Drugs 0.000 claims description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 3
- 229960002411 imatinib Drugs 0.000 claims description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims description 3
- 229960002014 ixabepilone Drugs 0.000 claims description 3
- 229960004891 lapatinib Drugs 0.000 claims description 3
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 3
- 229960003881 letrozole Drugs 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960004857 mitomycin Drugs 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 claims description 3
- 229960000801 nelarabine Drugs 0.000 claims description 3
- 229960001346 nilotinib Drugs 0.000 claims description 3
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 3
- 229950011068 niraparib Drugs 0.000 claims description 3
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims description 3
- 229960000572 olaparib Drugs 0.000 claims description 3
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 229960004390 palbociclib Drugs 0.000 claims description 3
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001972 panitumumab Drugs 0.000 claims description 3
- 229960005184 panobinostat Drugs 0.000 claims description 3
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims description 3
- 229960000639 pazopanib Drugs 0.000 claims description 3
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 3
- 229960005079 pemetrexed Drugs 0.000 claims description 3
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 3
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 claims description 3
- 229960000214 pralatrexate Drugs 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 229960002633 ramucirumab Drugs 0.000 claims description 3
- 229950004707 rucaparib Drugs 0.000 claims description 3
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229940073458 senaparib Drugs 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 229960003787 sorafenib Drugs 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 229960001796 sunitinib Drugs 0.000 claims description 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 3
- 229950004550 talazoparib Drugs 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 229960004964 temozolomide Drugs 0.000 claims description 3
- 229960003087 tioguanine Drugs 0.000 claims description 3
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- 229960005267 tositumomab Drugs 0.000 claims description 3
- 229960000575 trastuzumab Drugs 0.000 claims description 3
- 229960001612 trastuzumab emtansine Drugs 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 3
- 229960002066 vinorelbine Drugs 0.000 claims description 3
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 3
- 229960000237 vorinostat Drugs 0.000 claims description 3
- AYLPPPFRLPQFAK-AWEZNQCLSA-N 5-[[5-[4-bromo-2-methoxy-6-[[(2S)-thiomorpholin-2-yl]methoxy]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile Chemical compound BrC1=CC(=C(C(=C1)OC[C@@H]1CNCCS1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC AYLPPPFRLPQFAK-AWEZNQCLSA-N 0.000 claims description 2
- ZFZSFVOCHSBDDU-AWEZNQCLSA-N 5-[[5-[4-fluoro-2-methoxy-6-[[(2S)-thiomorpholin-2-yl]methoxy]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile Chemical compound FC1=CC(=C(C(=C1)OC[C@@H]1CNCCS1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC ZFZSFVOCHSBDDU-AWEZNQCLSA-N 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- YWVTXXOUSAFJJV-HNNXBMFYSA-N COC1=C(C(=CC(=C1)C)OC[C@@H]1CNCCS1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N Chemical compound COC1=C(C(=CC(=C1)C)OC[C@@H]1CNCCS1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N YWVTXXOUSAFJJV-HNNXBMFYSA-N 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- NVPZTZMARYWGHU-AWEZNQCLSA-N ClC1=CC(=C(C(=C1)OC[C@@H]1CNCCS1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC Chemical compound ClC1=CC(=C(C(=C1)OC[C@@H]1CNCCS1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)OC NVPZTZMARYWGHU-AWEZNQCLSA-N 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 229930188522 aclacinomycin Natural products 0.000 claims description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims description 2
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 2
- 229960001573 cabazitaxel Drugs 0.000 claims description 2
- 208000002458 carcinoid tumor Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 208000037244 polycythemia vera Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 14
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 7
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims 2
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 229960001614 levamisole Drugs 0.000 claims 2
- 210000003936 merozoite Anatomy 0.000 claims 2
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 8
- 230000002085 persistent effect Effects 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 33
- 239000000243 solution Substances 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000012043 crude product Substances 0.000 description 30
- 125000005843 halogen group Chemical group 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000000047 product Substances 0.000 description 23
- 239000007787 solid Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 22
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 235000019253 formic acid Nutrition 0.000 description 11
- UENLHUMCIOWYQN-UHFFFAOYSA-N 2'-Hydroxy-6'-methoxyacetophenone Chemical compound COC1=CC=CC(O)=C1C(C)=O UENLHUMCIOWYQN-UHFFFAOYSA-N 0.000 description 10
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- JDDPITNKUXPLSB-UHFFFAOYSA-N tert-butyl morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOCC1 JDDPITNKUXPLSB-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000002953 preparative HPLC Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 7
- GTYRFWMSDBGPTI-UHFFFAOYSA-N 5-chloropyrazine-2-carbonitrile Chemical compound ClC1=CN=C(C#N)C=N1 GTYRFWMSDBGPTI-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 7
- 125000002252 acyl group Chemical group 0.000 description 6
- 239000012737 fresh medium Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- FJYBLMJHXRWDAQ-MRVPVSSYSA-N tert-butyl (2r)-2-(hydroxymethyl)morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCO[C@@H](CO)C1 FJYBLMJHXRWDAQ-MRVPVSSYSA-N 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 230000018199 S phase Effects 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- DGDARTXQYQWIDD-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1.CC(C)(C)OC(=O)N1CCCCC1 DGDARTXQYQWIDD-UHFFFAOYSA-N 0.000 description 5
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 4
- CPKLCRCTCGPXBO-UHFFFAOYSA-N 5-[[5-(2-hydroxy-6-methoxyphenyl)-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile dihydrochloride Chemical compound Cl.Cl.COc1cccc(O)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1 CPKLCRCTCGPXBO-UHFFFAOYSA-N 0.000 description 4
- DLFOGKWKMNGAAE-UHFFFAOYSA-N 5-[[5-[2-methoxy-6-[(4-methoxyphenyl)methoxy]phenyl]-1h-pyrazol-3-yl]amino]pyrazine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1COC1=CC=CC(OC)=C1C1=CC(NC=2N=CC(=NC=2)C#N)=NN1 DLFOGKWKMNGAAE-UHFFFAOYSA-N 0.000 description 4
- 235000019489 Almond oil Nutrition 0.000 description 4
- BYVSWOHUADMTFE-UHFFFAOYSA-N COC=1C(=C(C=CC=1)O)C1=CC=NO1 Chemical compound COC=1C(=C(C=CC=1)O)C1=CC=NO1 BYVSWOHUADMTFE-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000008168 almond oil Substances 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000012820 cell cycle checkpoint Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- FJYBLMJHXRWDAQ-QMMMGPOBSA-N tert-butyl (2s)-2-(hydroxymethyl)morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCO[C@H](CO)C1 FJYBLMJHXRWDAQ-QMMMGPOBSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- RSNLDCUXHLFIRF-UHFFFAOYSA-N 1-[2-methoxy-6-[(4-methoxyphenyl)methoxy]phenyl]ethanone Chemical compound C1=CC(OC)=CC=C1COC1=CC=CC(OC)=C1C(C)=O RSNLDCUXHLFIRF-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- DWIVNCRPMBXLGT-FOKLQQMPSA-N COC1=C(C(=CC=C1)OCC1=CC=C(C=C1)OC)C(/C=C(/S(=O)(=O)C)\NC=1N=CC(=NC=1)C#N)=O Chemical compound COC1=C(C(=CC=C1)OCC1=CC=C(C=C1)OC)C(/C=C(/S(=O)(=O)C)\NC=1N=CC(=NC=1)C#N)=O DWIVNCRPMBXLGT-FOKLQQMPSA-N 0.000 description 3
- XLWWEIINXWMPPY-UHFFFAOYSA-N COC1=C(C(=CC=C1)OCC1=CC=C(C=C1)OC)C(C=C(S(=O)(=O)C)S(=O)(=O)C)=O Chemical compound COC1=C(C(=CC=C1)OCC1=CC=C(C=C1)OC)C(C=C(S(=O)(=O)C)S(=O)(=O)C)=O XLWWEIINXWMPPY-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 3
- 101000580039 Homo sapiens Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 description 3
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 125000004990 dihydroxyalkyl group Chemical group 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000028617 response to DNA damage stimulus Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- VYUBDPISDDEPPM-BQYQJAHWSA-N (E)-3-(dimethylamino)-1-(2-hydroxy-6-methoxyphenyl)prop-2-en-1-one Chemical compound CN(/C=C/C(=O)C1=C(C=CC=C1OC)O)C VYUBDPISDDEPPM-BQYQJAHWSA-N 0.000 description 2
- OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 description 2
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 2
- VYANAPRTDDQFJY-UHFFFAOYSA-N 5-aminopyrazine-2-carbonitrile Chemical compound NC1=CN=C(C#N)C=N1 VYANAPRTDDQFJY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PWWFHKXIWZBJTB-NRFANRHFSA-N CC(C)(C)OC(N1C[C@H](OC2=C(C3=CC(NC4=NC=C(C#N)N=C4)=NN3)C(OC)=CC=C2)OCC1)=O Chemical compound CC(C)(C)OC(N1C[C@H](OC2=C(C3=CC(NC4=NC=C(C#N)N=C4)=NN3)C(OC)=CC=C2)OCC1)=O PWWFHKXIWZBJTB-NRFANRHFSA-N 0.000 description 2
- CGNQTYNEUPBUAO-HNNXBMFYSA-N COC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1C)C#N Chemical compound COC1=C(C(=CC=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1C)C#N CGNQTYNEUPBUAO-HNNXBMFYSA-N 0.000 description 2
- AOEPRAJSXTWBKZ-AWEZNQCLSA-N COC1=CC=CC(=C1C1=CC=NO1)OC[C@H]1OCCN(C1)C(=O)OC(C)(C)C Chemical compound COC1=CC=CC(=C1C1=CC=NO1)OC[C@H]1OCCN(C1)C(=O)OC(C)(C)C AOEPRAJSXTWBKZ-AWEZNQCLSA-N 0.000 description 2
- GAAOPPGIGKAQKU-ZDUSSCGKSA-N COC1=CC=CC(=C1C=1NN=C(C=1)N)OC[C@H]1OCCN(C1)C(=O)OC(C)(C)C Chemical compound COC1=CC=CC(=C1C=1NN=C(C=1)N)OC[C@H]1OCCN(C1)C(=O)OC(C)(C)C GAAOPPGIGKAQKU-ZDUSSCGKSA-N 0.000 description 2
- MOXVCOAFBQOXJV-LBPRGKRZSA-N ClC1=CC(=C(C(=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)F Chemical compound ClC1=CC(=C(C(=C1)OC[C@@H]1CNCCC1)C1=CC(=NN1)NC=1N=CC(=NC=1)C#N)F MOXVCOAFBQOXJV-LBPRGKRZSA-N 0.000 description 2
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 2
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 2
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 2
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 239000012635 anticancer drug combination Substances 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229940046044 combinations of antineoplastic agent Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- CTJYSVRXJDACIO-UHFFFAOYSA-N tert-butyl thiomorpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCSCC1 CTJYSVRXJDACIO-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006823 (C1-C6) acyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 125000005960 1,4-diazepanyl group Chemical group 0.000 description 1
- ABJFBJGGLJVMAQ-UHFFFAOYSA-N 1,4-dihydroquinoxaline-2,3-dione Chemical compound C1=CC=C2NC(=O)C(=O)NC2=C1 ABJFBJGGLJVMAQ-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- NVVPBUKFNJIOME-UHFFFAOYSA-N 1-(2-amino-6-methoxyphenyl)ethanone Chemical compound COC1=CC=CC(N)=C1C(C)=O NVVPBUKFNJIOME-UHFFFAOYSA-N 0.000 description 1
- FXKOWMXEFZGVHC-UHFFFAOYSA-N 1-(2-ethoxy-6-hydroxyphenyl)ethanone Chemical compound CCOC1=CC=CC(O)=C1C(C)=O FXKOWMXEFZGVHC-UHFFFAOYSA-N 0.000 description 1
- PSNPXFMLAVLPPP-UHFFFAOYSA-N 1-(2-fluoro-6-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=C(O)C=CC=C1F PSNPXFMLAVLPPP-UHFFFAOYSA-N 0.000 description 1
- QYPIGDXWBIASMZ-UHFFFAOYSA-N 1-(2-hydroxy-6-methoxy-4-methylphenyl)ethanone Chemical compound COC1=CC(C)=CC(O)=C1C(C)=O QYPIGDXWBIASMZ-UHFFFAOYSA-N 0.000 description 1
- JTWOWWUFCYIVIB-UHFFFAOYSA-N 1-(3-chloro-6-hydroxy-2-methoxyphenyl)ethanone Chemical compound COC1=C(Cl)C=CC(O)=C1C(C)=O JTWOWWUFCYIVIB-UHFFFAOYSA-N 0.000 description 1
- XTNQIXIOSDPNCJ-UHFFFAOYSA-N 1-(4-chloro-2-hydroxy-6-methoxyphenyl)ethanone Chemical compound COC1=CC(Cl)=CC(O)=C1C(C)=O XTNQIXIOSDPNCJ-UHFFFAOYSA-N 0.000 description 1
- AMDXYFRUBRLXGH-UHFFFAOYSA-N 1-[2-hydroxy-6-(trifluoromethoxy)phenyl]ethanone Chemical group CC(=O)C1=C(O)C=CC=C1OC(F)(F)F AMDXYFRUBRLXGH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 description 1
- FSKYZRCACCHDGR-UHFFFAOYSA-N 1h-pyrido[3,2-d]pyrimidin-4-one Chemical compound C1=CN=C2C(=O)N=CNC2=C1 FSKYZRCACCHDGR-UHFFFAOYSA-N 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical class C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 description 1
- AIEGIFIEQXZBCP-UHFFFAOYSA-N 2-chloro-5-(trifluoromethyl)pyrazine Chemical compound FC(F)(F)C1=CN=C(Cl)C=N1 AIEGIFIEQXZBCP-UHFFFAOYSA-N 0.000 description 1
- XSDAJECCWPYVGW-UHFFFAOYSA-N 2-chloro-5-methylpyrazine Chemical compound CC1=CN=C(Cl)C=N1 XSDAJECCWPYVGW-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- DMSHUVBQFSNBBL-UHFFFAOYSA-N 5-bromopyridine-2-carbonitrile Chemical group BrC1=CC=C(C#N)N=C1 DMSHUVBQFSNBBL-UHFFFAOYSA-N 0.000 description 1
- FOHUMFIQHBSPGD-UHFFFAOYSA-N 7-aminoisochromen-1-one Chemical compound C1=COC(=O)C2=CC(N)=CC=C21 FOHUMFIQHBSPGD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- MAJIAAXLBBQHCS-UHFFFAOYSA-N CCCCP(CCCC)(CCCC)CC#N Chemical compound CCCCP(CCCC)(CCCC)CC#N MAJIAAXLBBQHCS-UHFFFAOYSA-N 0.000 description 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 description 1
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RPSXOEPRRNOANU-UHFFFAOYSA-N FC1=CC(=C(C(=C1)OC)C(C)=O)O Chemical compound FC1=CC(=C(C(=C1)OC)C(C)=O)O RPSXOEPRRNOANU-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- ZPKVEWXGHFASQJ-AWEZNQCLSA-N N#CCC(=O)C1=C(C=CC=C1OC)OC[C@H]1OCCN(C1)C(=O)OC(C)(C)C Chemical compound N#CCC(=O)C1=C(C=CC=C1OC)OC[C@H]1OCCN(C1)C(=O)OC(C)(C)C ZPKVEWXGHFASQJ-AWEZNQCLSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- HHAIXNHKPAADOF-UHFFFAOYSA-N ONC(CO)(CO)CO.[Na] Chemical compound ONC(CO)(CO)CO.[Na] HHAIXNHKPAADOF-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 239000012391 XPhos Pd G2 Substances 0.000 description 1
- ROTONRWJLXYJBD-LURJTMIESA-N [(2s)-oxan-2-yl]methanol Chemical group OC[C@@H]1CCCCO1 ROTONRWJLXYJBD-LURJTMIESA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- IUEWAGVJRJORLA-HZPDHXFCSA-N bmn-673 Chemical compound CN1N=CN=C1[C@H]1C(NNC(=O)C2=CC(F)=C3)=C2C3=N[C@@H]1C1=CC=C(F)C=C1 IUEWAGVJRJORLA-HZPDHXFCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- RSLSVURFMXHEEU-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[3-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylaniline Chemical compound [Pd+]Cl.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC(P(C2CCCCC2)C2CCCCC2)=C1 RSLSVURFMXHEEU-UHFFFAOYSA-M 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001793 isothiazol-3-yl group Chemical group [H]C1=C([H])C(*)=NS1 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 1
- 229960003648 ixazomib Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000001820 oxy group Chemical class [*:1]O[*:2] 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- OJCLHERKFHHUTB-VIFPVBQESA-N tert-butyl (3s)-3-(hydroxymethyl)piperidine-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CCC[C@H](CO)C1 OJCLHERKFHHUTB-VIFPVBQESA-N 0.000 description 1
- HKIGXXRMJFUUKV-QMMMGPOBSA-N tert-butyl (3s)-3-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CC[C@H](CO)C1 HKIGXXRMJFUUKV-QMMMGPOBSA-N 0.000 description 1
- AXZDMSKEPOXUIO-UHFFFAOYSA-N tert-butyl 2-(hydroxymethyl)thiomorpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCSC(CO)C1 AXZDMSKEPOXUIO-UHFFFAOYSA-N 0.000 description 1
- CTEDVGRUGMPBHE-UHFFFAOYSA-N tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CCC(CO)CC1 CTEDVGRUGMPBHE-UHFFFAOYSA-N 0.000 description 1
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 1
- HODDIXHTISUNRH-UHFFFAOYSA-N tert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1PC(C)(C)C HODDIXHTISUNRH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 1
- 229960001183 venetoclax Drugs 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
技术领域
本发明属于药物化学领域。本发明涉及3,5-二取代吡唑化合物,及其作为治疗上有效的激酶抑制剂和抗癌药物的应用。
背景技术
真核细胞的生长、增殖的过程是通过准确复制母细胞的遗传信息并通过染色体的有丝分裂产生两个相同的子细胞。这种细胞的增殖、分裂过程被称为细胞周期,包括了细胞从一次分裂完成开始,到下一次分裂完成的整个过程。细胞周期包括四个阶段:有丝分裂后的蛋白质,RNA等大量合成的G1期;DNA复制的S期;有丝分裂前的准备阶段G2期和细胞进行有丝分裂的M期。为了保证细胞内的遗传物质的完整性与准确性,细胞内有一套复杂而精密的信号通路来监测DNA损伤并作出相应的应答,如DNA修复、细胞周期检验点、细胞凋亡等,这套信号通路网络称为DNA损伤应答(DNA-damage-response,DDR)。
当DNA损伤发生时,细胞周期检验点会被激活:通过G1/S期检验点阻止细胞进入S期;通过Intra-S期或S期检验点延迟S期进程;通过G2/M期检验点阻碍细胞进入有丝分裂(Lobrich M等,Nature reviews Cancer 2007,7(11):861-869)。在应答DNA损伤反应的过程中,存在着一系列复杂的修复通路介导受损DNA的检测和修复,而细胞周期检测点激酶(CHK1和CHK2)则在DNA的损伤修复信号传导通路中起到了非常重要的作用。
CHK1蛋白属于丝氨酸/苏氨酸激酶蛋白(Sanchez Y等,Science,1997,277(5331):1497-1501),是调控G2/M细胞周期检验点的ATR-CHK1-CDC25C损伤反应途径的核心组成部分。细胞在识别DNA损伤信号后激活ATR,磷酸化CHK1上的多个丝氨酸位点,将CHK1激活,活化的CHK1进一步磷酸化下游的CDC25,导致CDC25降解,从而阻止CDC25对CDK1和CDK2的活化作用,使CDK1和CDK2失活,进而阻止细胞周期进程,使细胞进行DNA修复而存活(Carrassa L等,Cell Cycle 2011,10(13):2121-2128)。因此,靶向CHK1能干扰DNA损伤的修复,允许不可修复的DNA损伤累积并最终导致细胞的死亡。
CHK1蛋白激酶在乳腺癌、结肠癌、肝癌和胃癌等多种肿瘤中高表达。一些癌细胞对化疗和放疗及其它抗癌药物的不敏感或耐药,往往与CHK1的过度活化有关(Bao S等,Nature 2006,444(7120):756-760)。通过解除CHK1对细胞周期检验点的阻滞作用进而促使肿瘤细胞凋亡的机制成为了目前肿瘤研究的热点,同时也是CHK1抑制剂的研究基础。
已有多种CHK1激酶抑制剂公开,例如,WO03/10444和WO2005/072733公开了作为CHK1激酶抑制剂的芳基/杂芳基脲化合物;WO02/070494、WO2006/021002、WO2006/105262和WO2006/014359公开了作为CHK1激酶抑制剂的取代的尿素化合物;WO2005/009435、WO2010/077758、WO2012/064548、WO2015/120390和WO2017/132928公开了作为CHK1激酶抑制剂的取代的吡唑化合物。
然而,仍需要可作为CHK1潜在抑制剂且对癌症治疗有益的新颖化合物。
发明内容
本发明提供结构如式I、IIa、IIb、III和IV所示的新颖的3,5-二取代吡唑化合物或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药,作为激酶抑制剂,特别是CHK1激酶抑制剂。
本发明还提供了包含有效量的式I、IIa、IIb、III和IV化合物或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药的药用组合物,用来治疗癌症。
在一具体实施例中,所述药用组合物还可含有一种或多种可药用载体或稀释剂,用来治疗癌症。
在一具体实施例中,所述药用组合物还可含有至少一种已知的抗癌药物或所述抗癌药物的可药用盐,用来治疗癌症。
本发明也涉及到结构式I、IIa、IIb、III和IV的新颖化合物或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药的制备方法。
具体实施方式
应理解的是,本文所述的各实施方案的特征可任意组合,形成本文的技术方案;本文对各基团的定义适用于本文所述任一实施方案,例如,本文对烷基的取代基的定义适用于本文所述任一实施方案,除非该实施方案已清楚定义了烷基的取代基。
本文所用“氢(H)”包括其同位素氘(D)和氚(T)。
本文所用“烷基”是指烷基本身或是直链或支链高达十个碳原子的基团。有用的烷基包括直链或支链C1-C10烷基,优选C1-C6烷基。在某些实施方案中,烷基为C1-C4烷基。典型的C1-C10烷基包括甲基、乙基、丙基、异丙基、丁基、仲丁基、叔丁基、3-戊基、己基和辛基。
本文所用“亚烷基”是指如上文所定义的烷基,其位于两个其它化学基团之间并用于连接这两个其它化学基团。典型的亚烷基包括但不限于亚甲基、亚乙基、亚丙基和亚丁基。
本文所用“烷氧基”指被上述C1-C10烷基、优选C1-C6烷基或C1-C4烷基取代的氧基,例如甲氧基、乙氧基等。烷氧基中的烷基可被任选取代。烷氧基的取代基包括但不限于卤素、吗啉基、氨基和羧基(包括其酯基),所述氨基包括烷氨基和二烷氨基。
本文所述“氨基”可以–NR′R″表示,其中R′和R″各自独立为氢、可被任选取代的C1-C10烷基、可被任选取代的环烷基、可被任选取代的芳基、或可被任选取代的杂芳基;或者R′和R″一起与它们所连接的N形成可被任选取代的4元至7元环氨基团,所述环氨基团任选含有一个或多个(如2、3个)另外的选自O、N和S的杂原子。优选的氨基包括NH2、以及R′和R″中至少有一个是C1-C6烷基的基团。
本文所用“芳基”是指芳基本身或是作为其它基团的一部分,含有6到14个碳原子的单环、双环或三环芳族基团。芳基可被一个或多个本文所述的取代基取代。
有用的芳基包括C6-C14芳基,优选的是C6-C10芳基。典型的C6-C14芳基包括苯基、萘基、菲基、蒽基、茚基、薁基、联苯、亚联苯基和茀基。
有用的环烷基是C3-C8环烷基。典型的环烷基包括环丙基、环丁基、环戊基、环己基和环庚基。C3-C8环烷基可被一个或多个本文所述的取代基取代。
有用的卤素或卤素基团包括氟、氯、溴和碘。
有用的酰基氨基(酰氨基)是连接在氨基氮上的任何C1-C6酰基(烷酰基),例如乙酰氨基、丙酰氨基、丁酰氨基、戊酰氨基和己酰氨基,以及芳基取代的C1-C6酰基氨基,例如苯甲酰氨基。有用的酰基包括C1-C6酰基,如乙酰基。酰基可任选被选自芳基和卤素的基团取代,其中芳基可被任选取代。当被卤素取代时,卤素取代基的数量可在1-5个的范围内。被取代的酰基的例子包括氯乙酰基和五氟苯甲酰基等。
本文所用“杂环基”是指饱和或部分饱和的3-7元单环基团、7-10元双环基团、螺环基团或桥连环基团,它由碳原子和1-4个选自O、N、S的杂原子组成,其中杂原子氮和硫都可以被任意氧化,氮也可以任意季铵化。杂环基也包括所述双环体系中上述定义的任意杂环与苯环的稠并而成的稠杂环。如果产生的化合物是稳定的话,那么杂环的碳原子或氮原子可被取代。杂环基可被一个或多个本文所述的取代基取代。
有用的饱和或部分饱和杂环基团包括四氢呋喃基、四氢吡喃基、哌啶基、哌嗪基、1,4-二氮杂环庚烷基、吡咯烷基、咪唑烷基、咪唑啉基、二氢吲哚基、异二氢吲哚基、奎宁环基、吗啉基、异色满基、色满基、吡唑烷基、吡唑啉基、四氢异喹啉基、tetronoyl和tetramoyl,这些基团可被本文所述的一个或多个取代基取代。
本文所用“杂芳基”是指含有5–14个环原子,并且有6个,10个或14个π电子在环体系上共用的基团。杂芳基所含环原子是碳原子和1-3个选自氧、氮、硫的杂原子。杂芳基可被一个或多个本文所述的取代基取代。
有用的杂芳基包括噻吩基(苯硫基)、苯并[d]异噻唑-3-基、苯并[b]噻吩基、萘并[2,3-b]噻吩基、噻蒽基、呋喃基、吡喃基、异苯并呋喃基、色烯基、夹氧蒽基、噻吩恶基(phenoxanthiinyl)、吡咯基、咪唑基、吡唑基、吡啶基(包括但不限制于2-吡啶基、3-吡啶基和4-吡啶基)、吡嗪基、嘧啶基、哒嗪基、吲嗪基、异吲哚基、3H-吲哚基、吲哚基、吲唑基、嘌呤基、4H-喹嗪基、异喹啉基、喹啉基、酞嗪基、萘啶基、喹唑啉基、噌啉基、蝶啶基、咔唑基、β-咔啉基、菲啶基、吖啶基、萘嵌间二氮(杂)苯基、菲咯啉基、吩嗪基、异噻唑基、吩噻嗪基、异恶唑基、呋咱基、吩恶嗪基、1,4-二氢喹喔啉-2,3-二酮、7-氨基异香豆素、吡啶并嘧啶-4-酮、四氢吡啶并嘧啶基、四氢化五员[c]吡唑-3-基、苯并异恶唑基如1,2-苯并异恶唑-3-基、苯并咪唑基、2-羟吲哚基、噻重氮基、2-氧代苯并咪唑基、咪唑并哒嗪基、咪唑并吡啶基、三氮唑并哒嗪基、四氢吡啶并嘧啶基、吡唑并嘧啶基、吡咯并嘧啶基、吡咯并吡啶基、吡咯并吡嗪基或三氮唑并吡嗪基。当杂芳基在环中含有氮原子时,这样的氮原子可以呈N-氧化物形式,例如吡啶基N-氧化物、吡嗪基N-氧化物和嘧啶基N-氧化物。
本文中,除非另有说明,当被取代时,本文任一实施方案所述的烷基、环烷基、亚烷基、烷氧基、酰氨基、羰基、杂环基、芳基或杂芳基可被一个或多个(例如1、2、3或4个)选自以下基团的取代基取代:卤素、氰基、硝基、羟基、羧基、C1-C6酰氨基、C1-C6烷氧基、芳氧基、C1-C6烷基、C1-C6酰基、C6-C10芳基、C3-C8环烷基、杂环基或杂芳基和羰基等。其中取代基本身也可被任选取代。更优选地的取代基包括但不限于卤素、羰基、C1-C6酰氨基、C1-C6烷氧基、C1-C6烷基和C1-C6酰基。
应理解的是,本文各实施方案中,当取代基为杂环基、芳基或杂芳基时,该杂环基、芳基或杂芳基取代基的数量通常为1个。此外,应理解的是,本发明各基团之间的连接或取代均应满足键价理论;除非另有说明,否则,在不满足键价理论时,通常以H补齐。
具体来说,本发明提供下式I所示的化合物或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药:
其中,A0、A1和A2各自独立选自N或CRa;
R0选自氢、氰基、烷基、烷氧基或羰基,其中烷基、烷氧基或羰基可被任选取代;
R1选自卤素、羟基或可被任选取代的烷氧基;
R2-R4各自独立为氢、羟基、卤素、烷基、烷氧基、硝基、羰基或酰氨基,其中烷基、烷氧基、羰基或酰氨基可被任选取代;
R5选自氢、可被任选取代的烷基或可被任选取代的烷氧基;
R6选自氢、卤素或可被任选取代的烷基;
L是键、-C(Rb)2-、O、S或NRb;
Z是键或亚烷基;
Q是可被任选取代的杂环基;
Ra选自H、可被任选取代的烷基或卤素;
Rb各自独立为氢或可被任选取代的烷基。
式I化合物中,各烷基各自独立为C1-C6烷基,优选为C1-C4烷基;各亚烷基各自独立为C1-C6亚烷基,优选为C1-C4亚烷基;优选地,当烷基(包括烷氧基中的烷基)被取代时,其取代基可选自氨基、氰基、羟基、硝基、卤素和羧基等,取代基的数量可以是1-5个。例如,取代的烷基可以是羟基烷基、二羟基烷基和卤代烷基;取代的烷氧基可以是卤代烷氧基等。应理解,当取代基为氰基、硝基和羧基时,取代基数量通常为1个;当取代基为例如卤素时,可根据烷基碳链长度,取代基数量可达5个卤素基团;示例性的这类取代基如三氟甲基和五氟乙基等。
式I化合物中,优选地,Ra为H或C1-C3烷基;更优选地,A0和A1是N或CH;A2是N、CH或CCH3。更优选地,A0和A1是N;A2是CH。
式I化合物中,优选R0是氰基、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基。
式I化合物中,优选R1是卤素、羟基、C1-C3烷氧基或卤代C1-C3烷氧基。
式I化合物中,优选地,当R2-R4被取代时,取代基可选自羟基、卤素和氨基等。优选的R2-R4各自独立为氢、卤素、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基。更优选地,R2-R4各自独立为氢、卤素、C1-C3烷基或卤代C1-C3烷基。在一些实施方案中,R2-R4各自均为氢。在一些实施方案中,R2-R4中有且只有一个为卤素、C1-C3烷基或卤代C1-C3烷基,优选地其它基团为H。
式I化合物中,优选R5是氢或C1-C3烷基。
式I化合物中,优选R6是氢或C1-C3烷基。
式I化合物中,优选L是C1-C3亚烷基、O、S或NRb,优选的Rb是氢或C1-C3烷基。
式I化合物中,优选Z为C1-C3亚烷基,更优选为亚甲基。
式I化合物中,优选地,Q上的取代基选自卤素、羟基、氨基、羧基、任选取代的烷基、任选取代的烷氧基、任选取代的芳基、任选取代的杂芳基和任选取代的杂环基等。所述任选取代的烷基和烷氧基上的取代基可以是一个或多个选自氨基、卤素、羟基和羧基的取代基,如烷基可以被-NR′R″所取代,其中,R′、R″如文中所定义,优选各自独立为H或C1-C6烷基;所述任选取代的芳基、杂芳基和杂环基上的取代基可以是氨基、卤素、羟基、羧基、烷基和烷氧基中的一个或多个。优选地,Q上的取代基在连接位的邻位、间位和/或对位,而不是连接位置。
进一步优选地,式I化合物中,Q上的杂环原子选自N、O和S,优选Q含有1-3个杂原子,更优选地,Q为无取代的饱和的3-7元杂环基,或被1-2个任选取代的C1-C3烷基取代的饱和3-7元杂环基,其中,所述取代基位于连接位的邻位、间位和/或对位,而不位于连接位置。优选的杂环基包括但不限于哌啶基、哌嗪基、吡咯烷基、吗啉基、硫代吗啉基、四氢吡喃基和杂氮环丁烷基。优选的Q包括如下基团:
其中,*表示所述基团与化合物剩余部分的连接位置。
本发明式I所示的化合物可具有下式IIa所示的结构:
其中,A0选自N或CRa;
R0选自氢、氰基、烷基、烷氧基或羰基,其中烷基、烷氧基或羰基可被任选取代;
R1选自卤素、羟基或可被任选取代的烷氧基;
R2-R4各自独立为氢、卤素、烷基、烷氧基、硝基、羰基或酰氨基,其中烷基、烷氧基、羰基或酰氨基可被任选取代;
R5选自氢、可被任选取代的烷基或可被任选取代的烷氧基;
L是键、-C(Rb)2-、O、S或NRb;
Z是键或亚烷基;
Q是可被任选取代的杂环基,其中,所述取代基位于连接位的邻位、间位和/或对位,而不位于连接位置;
Ra选自H、可被任选取代的烷基或卤素;
Rb各自独立为氢或可被任选取代的烷基。
式IIa化合物中,各烷基各自独立为C1-C6烷基,优选为C1-C4烷基;各亚烷基各自独立为C1-C6亚烷基,优选为C1-C4亚烷基;优选地,当烷基(包括烷氧基中的烷基)被取代时,其取代基可选自氨基、氰基、羟基、硝基、卤素和羧基等,取代基的数量可以是1-5个。例如,取代的烷基可以是羟基烷基、二羟基烷基和卤代烷基;取代的烷氧基可以是卤代烷氧基等。应理解,当取代基为氰基、硝基和羧基时,取代基数量通常为1个;当取代基为例如卤素时,可根据烷基碳链长度,取代基数量可达5个卤素基团;示例性的这类取代基如三氟甲基和五氟乙基等。
式IIa化合物中,优选A0是N或CH。
式IIa化合物中,优选R0是氰基、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基。
式IIa化合物中,优选R1是卤素、羟基、C1-C3烷氧基或卤代C1-C3烷氧基,更优选为C1-C3烷氧基或卤代C1-C3烷氧基。
式IIa化合物中,优选地,当R2-R4被取代时,取代基可选自羟基、卤素和氨基等。优选的R2-R4各自独立为氢、卤素、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基。更优选地,R2-R4各自独立为氢、卤素、C1-C3烷基或卤代C1-C3烷基。在一些实施方案中,R2-R4各自均为氢。在一些实施方案中,R2-R4中有且只有一个为卤素、C1-C3烷基或卤代C1-C3烷基,优选地其它基团为H。
式IIa化合物中,优选R5是氢或C1-C3烷基。
式IIa化合物中,优选L是C1-C3亚烷基、O、S或NRb,优选的Rb是氢或C1-C3烷基。
式IIa化合物中,优选Z为C1-C3亚烷基,更优选为亚甲基。
式IIa化合物中,Q优选为哌啶基、哌嗪基、吡咯烷基、吗啉基、硫代吗啉基、四氢吡喃基和杂氮环丁烷基。优选地,Q上的取代基选自卤素、羟基、氨基、羧基、任选取代的烷基、任选取代的烷氧基、任选取代的芳基、任选取代的杂芳基和任选取代的杂环基等。所述任选取代的烷基和烷氧基上的取代基可以是一个或多个选自氨基、卤素、羟基和羧基的取代基,如烷基可以被-NR′R″所取代,其中,R′、R″如前文所定义,优选各自独立为H或C1-C6烷基;所述任选取代的芳基、杂芳基和杂环基上的取代基可以是氨基、卤素、羟基、羧基、烷基和烷氧基中的一个或多个。优选地,Q上的取代基在邻位、间位或对位。
进一步优选地,式IIa化合物中,Q上的杂环原子选自N、O和S,优选Q含有1-3个杂原子,更优选地,Q为无取代的饱和的3-7元杂环基,或被1-2个任选取代的C1-C3烷基取代的饱和3-7元杂环基,其中,所述取代基位于邻位、间位和/或对位,而不位于连接位置。优选的杂环基包括但不限于哌啶基、哌嗪基、吡咯烷基、吗啉基、硫代吗啉基、四氢吡喃基和杂氮环丁烷基。优选的Q包括如下基团:
其中,*表示所述基团与化合物剩余部分的连接位置。
本发明优选化合物的其中一组表示为式IIb化合物或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药:
其中,R0-R4和L如前文式I任一实施方案中所述;
Q为无取代的饱和的3-7元杂环基,或被1-2个任选取代的C1-C3烷基取代的饱和3-7元杂环基,其中,所述取代基位于连接位的邻位、间位和/或对位,而不位于连接位置。
式IIb化合物中,优选R0是氰基、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基。
式IIb化合物中,优选R1是卤素、羟基、C1-C3烷氧基或卤代C1-C3烷氧基。
式IIb化合物中,优选R2-R4各自独立为氢、卤素、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基;更为优选地,R2-R4各自独立为氢、卤素、C1-C3烷基或卤代C1-C3烷基;在一些实施方案中,R2-R4各自均为氢;在一些实施方案中,R2-R4中有且只有一个为卤素、C1-C3烷基或卤代C1-C3烷基。
式IIb化合物中,优选L是C1-C3亚烷基、O、S或NRb,优选的Rb是氢或C1-C3烷基。
式IIb化合物中,优选的Q中的杂环基包括但不限于哌啶基、哌嗪基、吡咯烷基、吗啉基、硫代吗啉基、四氢吡喃基和杂氮环丁烷基。优选的Q基团包括如下基团:
更优选的Q为如下基团:
其中,*表示所述基团与化合物剩余部分的连接位置。
本发明优选化合物的其中一组表示为式III化合物或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药:
其中,R1、R3和Q如前文式I、IIa和IIb任一实施方案中所述;
式III化合物中,优选R1是卤素、羟基、C1-C3烷氧基或卤代C1-C3烷氧基。
式III化合物中,优选R3是氢、卤素、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基;更优选地,R3是氢、卤素、C1-C3烷基或卤代C1-C3烷基。
式III化合物中,Q为无取代的饱和的3-7元杂环基,或被1-2个任选取代的C1-C3烷基取代的饱和3-7元杂环基,其中,所述取代基位于邻位、间位和/或对位,而不位于连接位置。优选的杂环基包括但不限于哌啶基、哌嗪基、吡咯烷基、吗啉基、硫代吗啉基、四氢吡喃基和杂氮环丁烷基。优选的Q包括如下基团:
更优选的Q为如下基团:
其中,*表示所述基团与化合物剩余部分的连接位置。
本发明优选化合物的其中一组表示为式IV化合物或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药:
其中,A0、A1、A2、R0-R6、L和Z如前文任一实施方案中所述;
A3是CH或N;
Q是3-7元杂环基;
R7选自卤素、羟基、氨基、羧基、任选取代的烷基、任选取代的烷氧基、任选取代的芳基、任选取代的杂芳基和任选取代的杂环基;
n为0-3,优选0-2。
式IV化合物中,优选Q为含有1-2个杂原子的3-7元的杂环基,杂原子选自O、S和N。优选地,Q选自哌啶基、哌嗪基、吡咯烷基、吗啉基、硫代吗啉基、四氢吡喃基和杂氮环丁烷基等。
式IV化合物中,优选R7为C1-C3烷基。在一些实施例中,n是0。
式IV化合物中,各烷基各自独立为C1-C6烷基,优选为C1-C4烷基;各亚烷基各自独立为C1-C6亚烷基,优选为C1-C4亚烷基;优选地,当烷基(包括烷氧基中的烷基)被取代时,其取代基可选自氨基、氰基、羟基、硝基、卤素和羧基等,取代基的数量可以是1-5个。例如,取代的烷基可以是羟基烷基、二羟基烷基和卤代烷基;取代的烷氧基可以是卤代烷氧基等。应理解,当取代基为氰基、硝基和羧基时,取代基数量通常为1个;当取代基为例如卤素时,可根据烷基碳链长度,取代基数量可达5个卤素基团;示例性的这类取代基如三氟甲基和五氟乙基等。
式IV化合物中,优选地,Ra为H或C1-C3烷基;更优选地,A0和A1是N或CH;A2是N、CH或CCH3。更优选地,A0和A1是N;A2是CH。
式IV化合物中,优选R0是氰基、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基。
式IV化合物中,优选R1是卤素、羟基、C1-C3烷氧基或卤代C1-C3烷氧基。
式IV化合物中,优选地,当R2-R4被取代时,取代基可选自羟基、卤素和氨基等。优选的R2-R4各自独立为氢、卤素、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基。更优选地,R2-R4各自独立为氢、卤素、C1-C3烷基或卤代C1-C3烷基。在一些实施方案中,R2-R4各自均为氢。在一些实施方案中,R2-R4中有且只有一个为卤素、C1-C3烷基或卤代C1-C3烷基,优选地其它基团为H。
式IV化合物中,优选R5是氢或C1-C3烷基;更优选R5是氢。
式IV化合物中,优选R6是氢、卤素或C1-C3烷基;更优选R6是氢。
式IV化合物中,优选L是C1-C3亚烷基、O、S或NRb,优选的Rb是氢或C1-C3烷基。
式IV化合物中,优选Z为C1-C3亚烷基,更优选为亚甲基。
式IV化合物中,优选被-(R7)n取代的环Q包括如下基团:
其中,*表示所述基团与化合物剩余部分的连接位置。
式IV化合物中,优选A0是N;A1是N;A2是CH;A3是CH;R0是氰基;R1是卤素、羟基或C1-C3烷氧基;R2是氢;R3是氢、卤素、C1-C3烷基或卤代C1-C3烷基;R4是氢;R5是氢;R6是氢;L是O;Z为C1-C3亚烷基,更优选为亚甲基;Q是未被取代的饱和3-7元杂环基;优选哌啶基、哌嗪基、吡咯烷基、吗啉基、硫代吗啉基、四氢吡喃基和杂氮环丁烷基;n是0。
式IV化合物中,优选A0是N;A1是N;A2是CH;A3是CH;R0是氰基;R1是C1-C3烷氧基;R2是氢;R3是氢、卤素或C1-C3烷基;R4是氢;R5是氢;R6是氢;L是O;Z为C1-C3亚烷基,更优选为亚甲基;环Q是无取代的饱和3-7元杂环基;优选哌啶基、吡咯烷基和硫代吗啉基;n是0。
式I优选的化合物实施例包括但不限于:
(S)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例1);
(S)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)氰基吡啶(实施例2);
(R)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例3);
(S)-5-((5-(2-甲氧基-6-((4-甲基吗啉-2-基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例4);
(S)-N-(5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)-5-(三氟甲基)吡嗪-2-胺(实施例5);
(S)-N-(5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)-5-甲基吡嗪-2-胺(实施例6);
(R)-5-((5-(2-甲氧基-6-(吗啉-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例7);
(S)-5-((5-(2-甲氧基-6-((四氢-2H-吡喃-2-基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例8);
(S)-5-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例9);
(S)-5-((5-(2-甲氧基-6-(哌嗪-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例10);
(S)-5-((5-(2-甲氧基-6-((1-甲基哌嗪-2-基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例11);
5-((5-(2-甲氧基-6-(哌啶-4-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例12);
(S)-5-((5-(2-甲氧基-6-(吡咯烷-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例13);
(S)-5-((5-(4-氟-2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例14);
(S)-5-((5-(3-氯-2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例15);
(S)-5-((5-(4-氯-2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例16);
(S)-5-((5-(3-氯-6-甲氧基-2-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例17);
(S)-5-((5-(4-溴-2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例18);
(S)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)-4-(三氟甲基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例19);
(S)-5-((5-(2-(吗啉-2-基甲氧基)-6-(三氟甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例20);
(S)-5-((5-(2-甲氧基-6-((吗啉-2-基甲基)氨基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例21);
(S)-5-((5-(2-甲氧基-6-(甲基(吗啉-2-基甲基)氨基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例22);
5-((5-(2-甲氧基-6-(2-(哌嗪-1-基)乙基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例23);
(S)-6-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)烟腈(实施例24);
(S)-6-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)哒嗪-3-甲腈(实施例25);
(S)-5-甲氧基-N-(5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)吡嗪-2-胺(实施例26);
(S)-5-乙基-N-(5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)吡嗪-2-胺(实施例27);
(S)-5-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)-3-甲基吡嗪-2-甲腈(实施例28);
(S)-5-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)-6-甲基吡嗪-2-甲腈(实施例29);
5-((5-(2-甲氧基-6-(哌啶-4-基氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例30);
5-((5-(2-(杂氮环丁烷-3-基甲氧基)-6-甲氧基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例31);
(S)-5-((5-(2-甲氧基-6-((1-甲基哌啶-3-基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例32);
(R)-5-((5-(2-甲氧基-6-(哌啶-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例33);
(S)-5-((5-(2-甲氧基-6-((四氢-2H-吡喃-3-基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例34);
(S)-5-((5-(2-乙氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例35);
(S)-5-((5-(2-异丙氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例36);
(S)-5-((5-(3-氟-2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例37);
(S)-5-((5-(4-氟-2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例38);
(S)-5-((5-(4-氟-2-甲氧基-6-(四氢吡咯-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例39);
(S)-5-((5-(4-氯-2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例40);
(S)-5-((5-(4-溴-2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例41);
(S)-5-((5-(2-甲氧基-3-甲基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例42);
(S)-5-((5-(2-甲氧基-4-甲基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例43);
(S)-5-((5-(2-甲氧基-4-甲基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例44);
(S)-5-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)-4-(三氟甲基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例45);
(S)-5-((5-(2-氟-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例46);
(S)-5-((5-(2-氯-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例47);
(S)-5-((5-(2-羟基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例48);
(S)-5-((5-(2-((4,4-二甲基哌啶-3-基)甲氧基)-6-甲氧基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例49);
(S)-5-((5-(2-((4,4-二甲基哌啶-3-基)甲氧基)-4-氟-6-甲氧基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例50);
(S)-5-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-4-甲基-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例51);
(S)-5-((4-溴-5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例52);
5-((5-(2-(氮杂环丁烷-3-基甲氧基)-6-氟苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例53);
(S)-5-((5-(2-氟-6-(吡咯烷-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例54);
(S)-5-((5-(2-氟-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例55);
(S)-5-((5-(2,4-二氟-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例56);
(S)-5-((5-(4-氯-2-氟-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例57);
(S)-5-((5-(4-氯-2-氟-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例58);
(S)-5-((5-(4-溴-2-氟-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例59);
(S)-5-((5-(4-溴-2-氟-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例60);
5-((5-(2-(氮杂环丁烷-3-基甲氧基)-6-氟-4-甲基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例61);
(S)-5-((5-(2-氟-4-甲基-6-(吡咯烷-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例62);
(S)-5-((5-(2-氟-4-甲基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例63);
(S)-5-((5-(2-氟-4-甲基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例64);
(R)-5-((5-(2-甲氧基-6-(吡咯烷-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例65);
(R)-5-((5-(4-氟-2-甲氧基-6-(吡咯烷-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例66);
5-((5-(2-(氮杂环丁烷-3-基甲氧基)-4-氯-6-甲氧基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例67);
(S)-5-((5-(4-氯-2-甲氧基-6-(吡咯烷-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例68);
5-((5-(2-(氮杂环丁烷-3-基甲氧基)-4-溴-6-甲氧基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例69);
(S)-5-((5-(4-溴-2-甲氧基-6-(吡咯烷-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例70);
(R)-5-((5-(4-溴-2-甲氧基-6-(吡咯烷-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例71);
5-((5-(2-(氮杂环丁烷-3-基甲氧基)-6-甲氧基-4-甲基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例72);
(S)-5-((5-(2-甲氧基-4-甲基-6-(吡咯烷-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例73);
(R)-5-((5-(2-甲氧基-4-甲基-6-(吡咯烷-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例74);
(S)-5-((5-(4-乙基-2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例75);
(S)-5-((5-(2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈和(R)-5-((5-(2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例76);
(S)-5-((5-(4-氟-2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈和(R)-5-((5-(4-氟-2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例77);
(S)-5-((5-(4-氯-2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈和(R)-5-((5-(4-氯-2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例78);
(S)-5-((5-(4-溴-2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈和(R)-5-((5-(4-溴-2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例79);
(S)-5-((5-(2-甲氧基-4-甲基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈和(R)-5-((5-(2-甲氧基-4-甲基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(实施例80);
或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药。
本发明的一些化合物可作为立体异构体,包括旋光异构体存在。本发明包括所有立体异构体和这样的立体异构体的外消旋混合物,以及可以根据本领域技术人员众所周知的方法分离出来的单独的对映体。
本发明中,可药用盐的例子包括无机和有机酸盐,例如盐酸盐、氢溴酸盐、磷酸盐、硫酸盐、柠檬酸盐、乳酸盐、酒石酸盐、马来酸盐、富马酸盐、扁桃酸盐和草酸盐;以及与碱例如钠羟基、三(羟基甲基)氨基甲烷(TRIS,氨丁三醇)和N-甲基葡糖胺形成的无机和有机碱盐。
本发明化合物的前药的实施例包括含有羧酸的化合物的简单酯(例如依据本领域已知方法通过与C1-C4醇缩合而获得的酯);含有羟基的化合物的酯(例如依据本领域已知方法通过与C1-C4羧酸、C3-C6二酸或其酸酐例如琥珀酸酐和富马酸酐缩合而获得的酯);含有氨基的化合物的亚胺(例如依据本领域已知方法通过与C1-C4醛或酮缩合而获得的亚胺);含有氨基的化合物的氨基甲酸酯,例如Leu等人(J.Med.Chem.42:3623-3628(1999))和Greenwald等人(J.Med.Chem.42:3657-3667(1999))描述的那些酯;含有醇的化合物的醛缩醇或酮缩醇(例如依据本领域已知方法通过与氯甲基甲基醚或氯甲基乙基醚缩合而获得的那些缩醇)。
本发明化合物可使用本领域技术人员已知的方法或本发明新方法制得。具体来说,具有式I的本发明化合物可如反应方案1中的反应实施例所示制得。1-(2-羟基-6-甲氧基苯基)乙酮和N,N-二甲基甲酰胺二甲基缩醛的混合物加热反应,得到产物(2E)-3-(二甲基氨基)-1-(2-羟基-6-甲氧基苯基)-2-丙烯基-1-酮。(2E)-3-(二甲基氨基)-1-(2-羟基-6-甲氧基苯基)-2-丙烯基-1-酮和盐酸羟胺在乙醇中加热反应,得到产物3-甲氧基-2-(1,2-恶唑-5-基)苯酚。将三苯基膦和偶氮二羧酸二异丙酯在四氢呋喃低温搅拌,然后加入3-甲氧基-2-(1,2-恶唑-5-基)苯酚和(2S)-2-(羟基甲基)吗啉-4-甲酸叔丁基酯,在室温下反应,得到产物(2S)-2-[3-甲氧基-2-(1,2-恶唑-5-基)苯氧甲基]吗啉-4-甲酸叔丁基酯。(2S)-2-[3-甲氧基-2-(1,2-恶唑-5-基)苯氧甲基]吗啉-4-甲酸叔丁基酯和氢氧化钾在乙醇和水中在室温下反应,得到产物(2S)-2-[2-(2-氰基乙酰基)-3-甲氧基苯氧甲基]吗啉-4-甲酸叔丁基酯。(2S)-2-[2-(2-氰基乙酰基)-3-甲氧基苯氧甲基]吗啉-4-甲酸叔丁基酯和水合肼在四氢呋喃、水和甲醇中搅拌,加入乙酸,加热反应得到产物(2S)-2-[2-(5-氨基-2H-吡唑-3-基)-3-甲氧基苯氧甲基]吗啉-4-甲酸叔丁基酯。(2S)-2-[2-(5-氨基-2H-吡唑-3-基)-3-甲氧基苯氧甲基]吗啉-4-甲酸叔丁基酯、5-氯吡嗪-2-甲腈和N-乙基吗啉在二甲基亚砜中加热反应,得到产物(2S)-2-(2-[5-[(5-氰基吡嗪-2-基)氨基]-2H-吡唑-3-基]-3-甲氧基苯氧基)吗啉-4-甲酸叔丁基酯。(2S)-2-(2-[5-[(5-氰基吡嗪-2-基)氨基]-2H-吡唑-3-基]-3-甲氧基苯氧基)吗啉-4-甲酸叔丁基酯和三氟乙酸在二氯甲烷中,在室温下反应,得到目标分子(S)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。
反应方案1
其它相关化合物可用类似方法制得。例如,用5-溴氰基吡啶替代5-氯吡嗪-2-甲腈可制得目标化合物(S)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)氰基吡啶;用2-氯-5-(三氟甲基)吡嗪替代5-氯吡嗪-2-甲腈可制得目标化合物(S)-N-(5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)-5-(三氟甲基)吡嗪-2-胺。用2-氯-5-甲基吡嗪替代5-氯吡嗪-2-甲腈可制得目标化合物(S)-N-(5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)-5-甲基吡嗪-2-胺。用(S)-(四氢-2H-吡喃-2-基)甲醇替代(2S)-2-(羟基甲基)吗啉-4-甲酸叔丁基酯可制得目标化合物(S)-5-((5-(2-甲氧基-6-((四氢-2H-吡喃-2-基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。用(S)-3-(羟基甲基)哌啶-1-甲酸叔丁基酯替代(2S)-2-(羟基甲基)吗啉-4-甲酸叔丁基酯可制得目标化合物(S)-5-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。用1-(4-氟-2-羟基-6-甲氧基苯基)-1-乙酮替代1-(2-羟基-6-甲氧基苯基)-1-乙酮可制得目标化合物(S)-5-((5-(4-氟-2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。用1-(3-氯-6-羟基-2-甲氧基苯基)-1-乙酮替代1-(2-羟基-6-甲氧基苯基)-1-乙酮可制得目标化合物(S)-5-((5-(3-氯-2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。用1-(2-羟基-6-(三氟甲氧基)苯基)-1-乙酮替代1-(2-羟基-6-甲氧基苯基)-1-乙酮可制得目标化合物(S)-5-((5-(2-(吗啉-2-基甲氧基)-6-(三氟甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。用1-(2-氨基-6-甲氧基苯基)-1-乙酮替代1-(2-羟基-6-甲氧基苯基)-1-乙酮可制得目标化合物(S)-5-((5-(2-甲氧基-6-((吗啉-2-基甲基)氨基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。用1-(2-羟基-6-乙氧基苯基)乙酮替代1-(2-羟基-6-甲氧基苯基)乙酮可制得目标化合物(S)-5-((5-(2-乙氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。用1-(4-氯-2-羟基-6-甲氧基苯基)乙酮替代1-(2-羟基-6-甲氧基苯基)乙酮可制得目标化合物(S)-5-((5-(4-氯-2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。用1-(4-甲基-2-羟基-6-甲氧基苯基)乙酮替代1-(2-羟基-6-甲氧基苯基)乙酮可制得目标化合物(S)-5-((5-(2-甲氧基-4-甲基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。用1-(2-氟-6-羟基苯基)乙酮替代1-(2-羟基-6-甲氧基苯基)乙酮可制得目标化合物(S)-5-((5-(2-氟-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。
本发明化合物可如反应方案2中的反应实施例所示制得。1-(2-羟基-6-甲氧基苯基)乙烯酮、对甲氧基苯甲基氯(PMBCl)和K2CO3在DMF中在室温下反应,得到产物1-(2-甲氧基-6-((4-甲氧基苄基)氧基)苯基)乙烷-1-酮。1-(2-甲氧基-6-((4-甲氧基苄基)氧基)苯基)乙烷-1-酮、t-BuOLi、CS2和MeI在无水DMSO中在室温下反应,得到产物1-(2-甲氧基-6-((4-甲氧基苯基)甲氧基)苯基)-3,3-双(甲基磺酰基)-2-丙烯-1-酮。5-氨基吡嗪-2-甲腈和NaH在THF中低温反应,然后加入1-(2-甲氧基-6-((4-甲氧基苯基)甲氧基)苯基)-3,3-双(甲基磺酰基)-2-丙烯-1-酮加热反应,得到产物5-(((E)-3-(2-甲氧基-6-((4-甲氧基苯基)甲氧基)苯基)-1-甲基磺酰基-3-氧代-1-丙烯基)氨基)吡嗪-2-甲腈。5-(((E)-3-(2-甲氧基-6-((4-甲氧基苯基)甲氧基)苯基)-1-甲基磺酰基-3-氧代-1-丙烯基)氨基)吡嗪-2-甲腈、AcOH和N2H4·H2O在EtOH中加热反应,得到产物5-((5-(2-甲氧基-6-((4-甲氧基苯基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。5-((5-(2-甲氧基-6-((4-甲氧基苯基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈在酸性条件下如HCl在二氧六环中在室温下反应脱保护,得到产物5-((5-(2-羟基-6-甲氧基-苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈二盐酸盐。5-((5-(2-羟基-6-甲氧基-苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈二盐酸盐、TEA、三苯基磷、偶氮二甲酸二异丙酯(DIAD)和(2R)-2-(羟基甲基)吗啉-4-甲酸叔丁基酯在THF中加热反应,得到产物(2R)-2-((2-[3-((5-氰基吡嗪-2-基)氨基)-1H-吡唑-5-基]-3-甲氧基苯氧基)甲基]吗啉-4-甲酸叔丁基酯。(2R)-2-((2-[3-((5-氰基吡嗪-2-基)氨基)-1H-吡唑-5-基]-3-甲氧基苯氧基)甲基]吗啉-4-甲酸叔丁基酯和TFA在DCM中在室温下反应,脱保护得到目标化合物(R)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。
反应方案2
其它相关化合物可用类似方法制得。例如,用(3S)-3-(羟基甲基)吗啉-4-甲酸丙烯酯替代(2R)-2-(羟基甲基)吗啉-4-甲酸叔丁基酯可制得目标化合物(R)-5-((5-(2-甲氧基-6-(吗啉-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。用1-烯丙基氧羰基-4-叔丁氧羰基-(S)-2-羟甲基哌嗪替代(2R)-2-(羟基甲基)吗啉-4-甲酸叔丁基酯可制得目标化合物(S)-5-((5-(2-甲氧基-6-(哌嗪-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。用4-(羟基甲基)哌啶-1-甲酸叔丁基酯替代(2R)-2-(羟基甲基)吗啉-4-甲酸叔丁基酯可制得目标化合物5-((5-(2-甲氧基-6-(哌啶-4-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。用(S)-3-(羟基甲基)吡咯烷-1-甲酸叔丁基酯替代(2R)-2-(羟基甲基)吗啉-4-甲酸叔丁基酯可制得目标化合物(S)-5-((5-(2-甲氧基-6-(吡咯烷-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。用4-羟基哌啶-1-甲酸叔丁基酯替代(2R)-2-(羟基甲基)吗啉-4-甲酸叔丁基酯可制得目标化合物5-((5-(2-甲氧基-6-(哌啶-4-基氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈。
本发明的一个重要方面是发现了式I化合物(包括本文所述的式IIa、IIb、III和IV化合物)是激酶抑制剂,特别是CHK1激酶抑制剂。因此,式I化合物(包括本文所述的式IIa、IIb、III和IV化合物)或其立体异构体、互变异构体、N-氧化物、水合物、溶剂化物或盐,或其混合物,或其前药可用于治疗CHK1持续性活化或DNA复制期间的高内在DNA损害或损伤相关的疾病、障碍和病症,或用于制备治疗CHK1持续性活化或DNA复制期间的高内在DNA损害或损伤相关的疾病、障碍和病症的药物。
本发明中,所述CHK1持续性活化或DNA复制期间的高内在DNA损害或损伤相关的疾病、障碍和病症包括癌症。癌症可以是实体瘤或血液肿瘤,包括但不限于肝癌、黑素瘤、霍奇金病、非霍奇金淋巴瘤、急性淋巴白血病、慢性淋巴白血病、多发性骨髓瘤、成神经细胞瘤、乳腺癌、卵巢癌、肺癌、维尔姆斯瘤、子宫颈癌、睾丸癌、软组织肉瘤、原发性巨球蛋白血症、膀胱癌、慢性粒细胞白血病、原发性脑癌、恶性黑素瘤、小细胞肺癌、胃癌、结肠癌、恶性胰腺胰岛瘤、恶性类癌性癌症、绒毛膜癌、蕈樣肉芽腫、头颈癌、骨原性肉瘤、胰腺癌、急性粒细胞白血病、毛细胞白血病、横纹肌肉瘤、卡波西肉瘤、泌尿生殖系统肿瘤病、甲状腺癌、食管癌、恶性高钙血症、子宫颈增生症、肾细胞癌、子宫内膜癌、真性红细胞增多症、特发性血小板增多症、肾上腺皮质癌、皮肤癌和前列腺癌。优选地,所述癌症与CHK1持续性活化或DNA复制期间的高内在DNA损害或损伤相关;所述“相关”意指在癌症的发生与发展中起作用,如导致了癌症的发生,和/或促进了癌症的发展或转移。
因此,本发明提供一种治疗或预防CHK1持续性活化或DNA复制期间的高内在DNA损害或损伤相关的疾病、障碍和病症的方法,所述方法包括给予需要的对象有效量的式I化合物(包括本文所述的式IIa、IIb、III和IV化合物)或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药,或含有有效量的式I化合物(包括本文所述的式IIa、IIb、III和IV化合物)或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药的药物组合物。本发明中,对象包括哺乳动物,更具体是人。
在实施本发明治疗方法时,给有一种或多种这些症状的病人施用有效量的药物制剂。所述药物制剂含有有效治疗浓度的式I化合物(包括本文所述的式IIa、IIb、III和IV化合物),被配制成用于口服、静脉注射、局部或外用给药的形式,用于治疗癌症和其他疾病。给药量是有效地改善或消除一个或多个病症的药量。对于特定疾病的治疗,有效量是足以改善或以某些方式减轻与疾病有关的症状的药量。这样的药量可作为单一剂量施用,或者可依据有效的治疗方案给药。给药量也许可治愈疾病,但是给药通常是为了改善疾病的症状。一般需要反复给药来实现所需的症状改善。
在另一个实施方案中提供了一种药用组合物,其含有作为CHK1抑制剂的本发明式I化合物(包括本文所述的式IIa、IIb、III和IV化合物)或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药与可药用载体。
本发明另一个实施方案涉及能有效地治疗癌症的药用组合物,其中包含作为CHK1抑制剂的本发明式I、IIa、IIb、III或IV化合物,或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药,与至少一种已知的抗癌药物或抗癌药物的可药用盐。所述至少一种已知的抗癌药物或其可药用盐包括其他的与DNA损伤和修复机理有关的抗癌药物,包括PARP抑制剂奥拉帕尼、Niraparib、Rucaparib、Talazoparib和Senaparib;HDAC抑制剂伏立诺他、罗咪地辛、帕比司他和贝利司他等等。所述至少一种已知的抗癌药物或其可药用盐还包括其他的与细胞分裂检测点有关的抗癌药物,包括CDK4/6抑制剂如帕博西尼,ATM/ATR抑制剂等等。其他可用于抗癌联合治疗的已知抗癌药物包括但不限于烷化剂例如白消安、马法兰、苯丁酸氮芥、环磷酰胺、异环磷酰胺、替莫唑胺、苯达莫司汀、顺铂、丝裂霉素C、博莱霉素和卡铂;拓扑异构酶I抑制剂例如喜树碱、伊立替康和托泊替康;拓扑异构酶Ⅱ抑制剂例如阿霉素、表阿霉素、阿克拉霉素、米托蒽醌、甲基羟基玫瑰树碱和铭托泊普;RNA/DNA抗代谢物例如5-氮杂胞苷、吉西他滨、5-氟尿嘧啶和甲氨蝶呤;DNA抗代谢物例如5-氟-2′-去氧尿苷、氟达拉滨,奈拉滨、阿糖胞苷、普拉曲沙、培美曲塞、羟基脲和硫代鸟嘌呤;抗有丝分裂剂例如秋水仙碱、长春碱、长春新碱、长春瑞滨、紫杉醇、伊沙匹隆、卡巴他赛和多西他赛;抗体例如单抗,帕尼单抗、耐措妥珠单抗、纳武单抗、派姆单抗、雷莫芦单抗、贝伐珠单抗、帕妥珠单抗、曲妥珠单抗、西妥昔单抗、奥滨尤妥珠单抗、奥法木单抗、利妥昔单抗、阿仑单抗、替伊莫单抗、托西莫单抗、本妥昔单抗、达雷木单抗、埃罗妥珠单抗、T-DM1、Ofatumumab、Dinutuximab、Blinatumomab、易普利姆玛、阿瓦斯丁、赫赛汀和美罗华;激酶抑制剂例如伊马替尼、吉非替尼、厄洛替尼、奥斯替尼、阿法替尼、赛立替尼、艾乐替尼、克唑替尼、埃罗替尼、拉帕替尼、索拉非尼、瑞格非尼、维罗非尼、达拉非尼、阿柏西普、舒尼替尼、尼罗替尼、达沙替尼、博舒替尼、普拉替尼、依鲁替尼、卡博替尼、乐伐替尼、凡德他尼、曲美替尼、卡比替尼、阿昔替尼、替西罗莫司、Idelalisib、帕唑帕尼、特癌适和依维莫司。其他可用于抗癌组合治疗的已知抗癌药物包括他莫昔芬、来曲唑、氟维司群、米托胍腙、奥曲肽、视黄酸、砒霜、唑来膦酸、硼替佐米、卡非佐米、Ixazomib、维莫德吉、索尼德吉、狄诺塞麦、萨力多胺、来那度胺、Venetoclax、Aldesleukin(重组人白介素-2)和Sipueucel-T(前列腺癌治疗疫苗)。
在实施本发明的方法时,本发明化合物与至少一种已知的抗癌药物可作为单一的药用组合物一起给药。或者,本发明化合物也可与至少一种已知抗癌药分开给药。在一个实施方案,本发明化合物和至少一种已知的抗癌药差不多同时给药,即所有的药物同时施用或陆续施用,只要化合物在血液中同时达到治疗浓度即可。在另外一个实施方案,本发明的化合物和至少一种已知的抗癌药根据各自的剂量方案给药,只要化合物在血液中达到治疗浓度即可。
本发明的另一个实施方案是一种生物耦合物,其含有本发明所述化合物,能作为激酶抑制剂有效抑制肿瘤。本发明的生物耦合物含有本发明所述的化合物和至少一种已知的有医疗作用的抗体,如赫赛汀或美罗华,或生长因子,如EGF或FGF,或细胞激素,如白细胞介素2或4,或任意能与细胞表面结合的分子,或由它们组成。该抗体与其他分子能把所述化合物递送到其靶点,使之成为有效的抗癌药物。此生物耦合物也可以提高有医疗作用的抗体,如赫赛汀或美罗华的抗癌效果。
本发明的另一实施例涉及一种能有效抑制肿瘤的药用组合物,包含式I、IIa、IIb、III或IV所示的CHK1抑制剂,或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药,与放射疗法联合治疗。在此实施例,本发明化合物与放射治疗可在相同时间或不同时间给药。
本发明的另一实施例涉及一种能有效的用于癌症手术后治疗的药用组合物,包含式I、IIa、IIb、III或IV所示的CHK1抑制剂,或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药。本发明还涉及用手术切除肿瘤,然后用本发明的药用组合物治疗该哺乳动物的癌症的治疗方法。
本发明的药用组合物包括所有本发明化合物的含有量能有效地实现其预期目标的药品制剂。虽然每个人的需求各不相同,本领域技术人员可确定药品制剂中每个部分的最佳剂量。一般情况下,所述化合物,或其可用药盐,对哺乳动物每天口服给药,药量按照约0.0025到50毫克/公斤体重。但最好是每公斤口服给药约0.01到10毫克/公斤。如果也施用一个已知的抗癌药物,其剂量应可有效地实现其预期的目的。这些已知的抗癌药物的最佳剂量是本领域技术人员所熟知的。
单位口服剂量可以包括约0.01到50毫克,最好是约0.1到10毫克的本发明化合物。单位剂量可给予一次或多次,每天为一片或多片,每片含有约0.1到50毫克,合宜地约0.25到10毫克的本发明化合物或其溶剂化物。
在外用制剂中,本发明化合物的浓度可以是每克载体约0.01到100毫克。
本发明化合物可作为未加工药品给药。本发明化合物也可以作为含有可药用载体(包括辅料和助剂)的一个合适的药物制剂的一部分给药。这些可药用载体有利于把化合物加工成可药用的药物制剂。优选的药物制剂,特别是那些口服的和优选的给药方式类型,如片剂,锭剂和胶囊,以及适合于注射或口服的溶液,包含约0.01%到99%,最好从约0.25%到75%的活性化合物以及辅料。
本发明的范围也包括本发明化合物的无毒性可药用盐。酸加成盐由混合一个无毒性可药用酸溶液和本发明的化合物溶液而形成。所述酸例如盐酸,富马酸,马来酸,琥珀酸,乙酸,柠檬酸,酒石酸,碳酸,磷酸,草酸等。碱加成盐由混合一个无毒性可药用碱溶液和本发明的化合物溶液而形成。所述碱例如氢氧化钠,氢氧化钾,氢胆碱,碳酸钠,三羟甲基氨基甲烷,N-甲基-葡萄糖胺等。
本发明的药物制剂可以给予任何哺乳动物,只要他们能获得本发明化合物的治疗效果。在这些哺乳动物中最为重要的是人类和兽医动物,虽然本发明不打算如此受限。
本发明的药物制剂可通过任何途径给药以达到其预期目的。例如,可以通过肠外,皮下,静脉,肌肉,腹腔内,透皮,口腔,鞘内,颅内,鼻腔或外用途径给药。作为替代或并行地,可以通过口服给药。药的剂量将根据病人的年龄,健康与体重,并行治疗的种类,治疗的频率,以及所需治疗效益来决定。
本发明的药物制剂可用已知的方式制造。例如,由传统的混合,制粒,制锭,溶解,或冷冻干燥过程制造。制造口服制剂时,可结合固体辅料和活性化合物,选择性研磨混合物。如果需要或必要时加入适量助剂后,加工颗粒混合物,获得片剂或锭剂芯。
合适的辅料特别是填料,例如糖类如乳糖或蔗糖,甘露醇或山梨醇;纤维素制剂和/或钙磷酸盐,例如磷酸三钙或磷酸氢钙;以及粘结剂,例如淀粉糊,包括玉米淀粉,小麦淀粉,大米淀粉,马铃薯淀粉,明胶,黄芪胶,甲基纤维素,羟丙基甲基纤维素,羧甲基纤维素钠,和/或聚乙烯吡咯烷酮。如果需要,可增加崩解剂,比如上面提到的淀粉,以及羧甲基淀粉,交联聚乙烯吡咯烷酮,琼脂,或褐藻酸或其盐,如海藻酸钠。辅助剂特别是流动调节剂和润滑剂,例如,硅石,滑石,硬脂酸或其盐,如硬脂酸镁或硬脂酸钙,和/或聚乙二醇。如果需要,可以给锭剂核芯提供可以抵抗胃液的合适包衣。为此,可以应用浓缩糖类溶液。这个溶液可以含有阿拉伯树胶,滑石,聚乙烯吡咯烷酮,聚乙二醇和/或二氧化钛,漆溶液和合适的有机溶剂或溶剂混合物。为了制备耐胃液的包衣,可使用适当的纤维素溶液,例如醋酸纤维素邻苯二甲酸或羟丙基甲基纤维素邻苯二甲酸。可向药片或锭剂核芯的包衣加入染料或色素。例如,用于识别或为了表征活性成分剂量的组合。
其他可口服的药物制剂包括明胶制成的压接式胶囊,以及用明胶和甘油或山梨醇等增塑剂制成的密封软胶囊。该压接式胶囊可含有颗粒形式的活性化合物,与填料例如乳糖;粘结剂例如淀粉;和/或润滑剂例如滑石粉或硬脂酸镁,以及稳定剂混合而成。在软胶囊,活性化合物最好是溶解或悬浮在适当的液体例如油脂或液体石蜡中,其中可加入稳定剂。
合适于肠外给药的制剂包括活性化合物的水溶液,如水溶性盐的溶液和碱性溶液。此外,可施用适当的活性化合物的油性注射悬浮液。合适的亲脂性溶剂或载体包括油脂例如香油,合成脂肪酸酯例如油酸乙酯或甘油三酯或聚乙二醇400,或氢化蓖麻油,或环糊精。水性注射悬浮液可含有增加悬浮液黏度的物质,例如羧甲基纤维素钠,山梨醇,和/或葡聚糖。也可以含有悬浮稳定剂。
按照本发明的一个方面,本发明的化合物采用外用和肠外配方,并用于治疗皮肤癌。
本发明的外用制剂可通过优选合适的载体来制成油剂,霜剂,乳液剂,药膏等。合适的载体包括植物或矿物油,白矿油(白软石蜡),支链脂肪或油脂,动物脂肪和高分子醇(大于C12)。优选的载体是活性成分能溶解在其中的那些载体。也可包括乳化剂,稳定剂,保湿剂和抗氧化剂,以及如果需要的话,给予颜色或香味的试剂。此外,这些外用制剂可包含透皮渗透增强剂。这种增强剂的例子可参见美国专利号3,989,816和4,444,762。
霜剂优选用矿物油,自乳化蜂蜡和水的混合物配制,与溶解于少量油例如杏仁油的活性成分混合而成。一个典型的霜剂例子包括约40份水,20份蜂蜡,40份矿物油和1份杏仁油。
药膏可以这样配制,将含有活性成分的植物油例如杏仁油和温热的软石蜡混合,然后使该混合物冷却。一个典型的药膏例子包括约30%重量的杏仁油和70%重量的白软石蜡。
本发明也涉及应用本发明的化合物制备治疗CHK1持续性活化或DNA复制期间的高内在DNA损害或损伤的相关的疾病、障碍和临床病症的药物。这些药物可包括上述药用组合物。
下列实施例是举例说明,而不是限制本发明的方法和制剂。其他对于本领域技术人员来说是显而易见的,和在临床治疗中通常会遇到的对各种条件和参数的适当修改和改进,都在本发明的精神和范围内。
实施例
一般性说明
所用试剂均是商品品质,溶剂均按照标准方法干燥纯化。使用电喷雾的单四级杆质谱仪(平台Ⅱ,安捷伦6110)分析质谱样品。使用Brücker Ascend 400核磁仪在400MHz记录1H NMR光谱,化学位移记录为以TMS作为内标(0.00ppm)从低场始以ppm为单位,耦合常数J值以Hz为单位。使用岛津LC-30ADsf分析化合物样品的光学纯度。
实施例1
(S)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈
a)(2E)-3-(二甲基氨基)-1-(2-羟基-6-甲氧基苯基)-2-丙烯基-1-酮:1-(2-羟基-6-甲氧基苯基)-1-乙酮(25g,150.4mmol)和N,N-二甲基甲酰胺二甲基缩醛(DMF-DMA,80.6mL,676.1mmol)的混合物在110℃下搅拌1小时。反应液用水(100mL)淬灭,有沉淀析出,过滤,固体用水洗(100mL×3),得到目标产物(30.5g,91%收率,黄色固体)。MS(ESI,m/z):222[M+H]+。
b)3-甲氧基-2-(1,2-恶唑-5-基)苯酚:将(2E)-3-(二甲基氨基)-1-(2-羟基-6-甲氧基苯基)-2-丙烯基-1-酮(8.2g,37.1mmol)和盐酸羟胺(2.3g,55.5mmol)在乙醇中的混合物在N2的保护下在70℃下搅拌1小时。反应液用水(100mL)淬灭,有沉淀析出,过滤,固体用水洗(200mL×3),得到目标产物(6.8g,95%收率,黄色固体)。MS(ESI,m/z):192[M+H]+。
c)(2S)-2-[3-甲氧基-2-(1,2-恶唑-5-基)苯氧甲基]吗啉-4-甲酸叔丁基酯:将三苯基膦(PPh3,5.5g,20.9mmol)和偶氮二羧酸二异丙酯(DIAD,4.2g,20.9mmol)在四氢呋喃(30mL)中的混合物在N2的保护下在0℃下搅拌30分钟。然后在0℃下向该反应中加入3-甲氧基-2-(1,2-恶唑-5-基)苯酚(2.0g,10.5mmol)和(2S)-2-(羟基甲基)吗啉-4-甲酸叔丁基酯(2.7g,12.6mmol)。反应混合物在室温下搅拌16小时。反应液用水(50mL)淬灭,用乙酸乙酯(80mL×3)萃取,合并有机相,用饱和食盐水(40mL×2)洗,用无水硫酸钠干燥。过滤,滤液减压浓缩得到粗产物,经硅胶柱层析(用乙酸乙酯的石油醚溶剂(1-50%)洗脱)纯化,得目标产物(1.5g,36%,灰白色固体)。MS(ESI,m/z):391[M+H]+。
d)(2S)-2-[2-(2-氰基乙酰基)-3-甲氧基苯氧甲基]吗啉-4-甲酸叔丁基酯:将(2S)-2-[3-甲氧基-2-(1,2-恶唑-5-基)苯氧甲基]吗啉-4-甲酸叔丁基酯(1.50g,3.8mmol)和氢氧化钾(0.43g,7.7mmol)在乙醇(15mL)和水(5mL)中的混合物在室温下搅拌16小时,反应液用乙酸乙酯(80mL×3)萃取,合并有机相,有机相用饱和食盐水(40mL×2)洗,用无水硫酸钠干燥。过滤,滤液减压浓缩得到粗产物,经硅胶柱层析(用乙酸乙酯的石油醚溶剂(1-50%)洗脱)纯化,得目标产物(648mg,65%收率,灰白色固体)。MS(ESI,m/z):391[M+H]+。
e)(2S)-2-[2-(5-氨基-2H-吡唑-3-基)-3-甲氧基苯氧甲基]吗啉-4-甲酸叔丁基酯:将(2S)-2-[2-(2-氰基乙酰基)-3-甲氧基苯氧甲基]吗啉-4-甲酸叔丁基酯(648mg,1.7mmol)和水合肼(0.35mL,2.5mmol,35%)在四氢呋喃(1mL)、水(1mL)和甲醇(2mL)中的混合物搅拌,并向其中加入乙酸(0.10mL,1.58mmol)。将反应混合物在120℃下搅拌3小时,降至室温后,用水(50mL)稀释,用乙酸乙酯(80mL×3)萃取,合并有机相,有机相用饱和食盐水(40mL×2)洗,用无水硫酸钠干燥。过滤,滤液减压浓缩得到粗产物,经硅胶柱层析(用甲醇的二氯甲烷溶剂(1-10%)洗脱)纯化,得目标产物(512mg,76%收率,灰白色固体)。MS(ESI,m/z):405[M+H]+。
f)(2S)-2-(2-[5-[(5-氰基吡嗪-2-基)氨基]-2H-吡唑-3-基]-3-甲氧基苯氧基)吗啉-4-甲酸叔丁基酯:向(2S)-2-[2-(5-氨基-2H-吡唑-3-基)-3-甲氧基苯氧甲基]吗啉-4-甲酸叔丁基酯(180mg,0.45mmol)和5-氯吡嗪-2-甲腈(71mg,0.51mmol)在二甲基亚砜(4mL)的混合物中加入N-乙基吗啉(48μL,0.534mmol)。反应混合物在N2的保护下在80℃下搅拌3小时,得到的反应液用水(20mL)稀释,用乙酸乙酯(30mL×3)萃取,合并有机相,有机相用饱和食盐水(40mL×2)洗,用无水硫酸钠干燥。过滤,滤液减压浓缩得到粗产物,经硅胶柱层析(用甲醇的二氯甲烷溶剂(1-10%)洗脱)纯化,得目标产物(154mg,68%收率,灰白色固体)。MS(ESI,m/z):508[M+H]+。
g)(S)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈:将(2S)-2-(2-[5-[(5-氰基吡嗪-2-基)氨基]-2H-吡唑-3-基]-3-甲氧基苯氧基)吗啉-4-甲酸叔丁基酯(120mg,0.236mmol)在二氯甲烷(1mL)中的溶液和三氟乙酸(0.2mL)在室温下搅拌1小时。反应液减压浓缩得到粗产物,经反相色谱柱纯化(XBridgeShield RP18OBD色谱柱,30*150mm,5μm;流动相A,水(10mM NH4HCO3),流动相B:乙腈;UV254nm)得到目标化合物(30mg,31%收率,灰白色固体)。
实施例2
(S)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)氰基吡啶
本实施例化合物采用类似于实施例1的方法制备得到。
实施例3
(R)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈
a)1-(2-甲氧基-6-((4-甲氧基苄基)氧基)苯基)乙烷-1-酮:向1-(2-羟基-6-甲氧基苯基)乙烯酮(2g,12.04mmol)的DMF(16mL)溶液中加入K2CO3(4.16g,30.09mmol),在25℃下搅拌30min。然后向上述反应混合物中逐滴加入对甲氧基苯甲基氯(PMBCl,2.26g,14.44mmol,1.97mL),反应混合物在25℃下搅拌12h。加入80mL水淬灭该反应,用EA(80mL×3)萃取,合并有机相,有机相用饱和氯化钠溶液(50mL×3)洗,用无水硫酸钠干燥,过滤,减压浓缩得到的残留物在PE(10mL)中在30℃下打浆10min,得到目标粗产物(3.12g,黄色固体,90.4%收率)。1H NMR(400MHz,CDCl3):δ7.31-7.29(m,2H),7.24(t,J=8.4Hz,1H),6.91-6.88(m,2H),6.61(d,J=4.4Hz,1H),6.57(d,J=4.4Hz,1H),5.02(s,2H),3.82-3.81(m,6H),2.47(s,3H)。
b)1-(2-甲氧基-6-((4-甲氧基苯基)甲氧基)苯基)-3,3-双(甲基磺酰基)-2-丙烯-1-酮:向t-BuOLi(615.11mg,7.68mmol,692.70uL)在无水DMSO(2mL)中的混合物中,在氮气保护下加入1-(2-甲氧基-6-((4-甲氧基苄基)氧基)苯基)乙烷-1-酮(1g,3.49mmol)。保持内温低于30℃,所得混合物搅拌30min,缓慢加入CS2(319.11mg,4.19mmol,253.26uL)。在30℃下搅拌1h,缓慢加入MeI(991.46mg,6.99mmol,434.85uL),保持内温低于30℃。所得混合物在30℃下搅拌1.5h。加入80mL水稀释混合物,用EA(30mL×3)萃取,合并有机相,有机相用无水硫酸钠干燥,过滤,减压浓缩得到的残留物在EA中在30℃下打浆15min,用MTBE(10mL×3)洗,得到目标粗产物(1.04g,黄色固体,76.5%收率)。MS(ESI,m/z):391.0[M+H]+。1HNMR(400MHz,CDCl3):δ7.31-7.29(m,2H),7.22(t,J=8.4Hz,1H),6.88-6.86(m,2H),6.59(t,J=8.8Hz,2H),6.26(s,1H),5.03(s,1H),3.81-3.75(m,6H),2.51(s,3H),2.31(s,3H)。
c)5-(((E)-3-(2-甲氧基-6-((4-甲氧基苯基)甲氧基)苯基)-1-甲基磺酰基-3-氧代-1-丙烯基)氨基)吡嗪-2-甲腈:将NaH(46.09mg,1.15mmol,60%纯度)和THF(3mL)的混合溶液,冷却至5-15℃,向其中分四份加入5-氨基吡嗪-2-甲腈(110.73mg,921.86umol)以控制氢气的释放,使产生的泡沫在添加的间隙消退保持温度在10℃。混合物搅拌90min,同时允许温度上升至15℃。向上述的反应混合物中分多份加入1-(2-甲氧基-6-((4-甲氧基苯基)甲氧基)苯基)-3,3-双(甲基磺酰基)-2-丙烯-1-酮(300mg,768.22umol)以控制泡沫的产生。混合物搅拌15min,然后加热回流在66℃下反应2h。将所得反应混合物倒入到冷水(40mL)中,用EA(40mL×3)萃取,合并有机相,有机相用无水硫酸钠干燥,过滤,减压浓缩得到的残留物,在30℃下在EA(10mL)中重结晶得到目标粗产物(231mg,黄色固体,65.1%收率)。MS(ESI,m/z):463.1[M+H]+。
d)5-((5-(2-甲氧基-6-((4-甲氧基苯基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈:5-(((E)-3-(2-甲氧基-6-((4-甲氧基苯基)甲氧基)苯基)-1-甲基磺酰基-3-氧代-1-丙烯基)氨基)吡嗪-2-甲腈(230mg,497.28umol)、AcOH(86.95mg,1.45mmol,82.81uL)和EtOH(5.5mL)的混合物用氮气置换反应瓶中的空气3次。然后逐滴加入N2H4·H2O(49.31mg,965.32umol,47.87uL,98%纯度),所得混合物在氮气保护下在65℃下搅拌1h。将反应混合物过滤得到滤饼,滤饼用EtOH(5mL×3)洗,得到目标粗产物(197mg,黄色固体,85.7%收率)。MS(ESI,m/z):429.1[M+H]+。
e)5-((5-(2-羟基-6-甲氧基-苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈二盐酸盐:向5-((5-(2-甲氧基-6-((4-甲氧基苯基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈(197mg,459.80umol)在二氧六环(6mL)的溶液中加入HCl二氧六环溶液(4M,5.75mL)。所得混合物在25℃下搅拌10h,然后减压浓缩得到目标粗产物(161mg,黄色固体,95.3%收率)。MS(ESI,m/z):309.1[M+H]+。
f)(2R)-2-((2-[3-((5-氰基吡嗪-2-基)氨基)-1H-吡唑-5-基]-3-甲氧基苯氧基)甲基]吗啉-4-甲酸叔丁基酯:冷却至-5℃,向5-((5-(2-羟基-6-甲氧基-苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈二盐酸盐(161mg,422.33umol)在THF(2mL)的溶液中加入TEA(105.69mg,1.04mmol,145.38uL)。所得混合液在-5℃下搅拌30min,得到混合物A。将三苯基磷(342.44mg,1.31mmol)在25℃下溶于THF(2mL)中,得到的无色澄清溶液在丙酮/冰浴下冷却至-5℃,向其中逐滴加入偶氮二甲酸二异丙酯(DIAD,253.44mg,1.25mmol,243.69uL),耗时20min,保持温度低于10℃。得到的厚白浆再次冷却至-5-0℃,将(2R)-2-(羟基甲基)吗啉-4-甲酸叔丁基酯(283.65mg,1.31mmol)溶于THF(2mL)中的溶液加入,混合物在-5℃下搅拌20min得到混合物B。在-5℃下,将混合物A逐滴加入到混合物B中,在50℃下搅拌30min。反应混合物减压浓缩后得到的残留物,经制备薄板层析(SiO2,PE:EA=1:1)纯化后,再经制备柱分离纯化得到目标粗产物(12mg,黄色固体,5.6%收率)。MS(ESI,m/z):508.2[M+H]+。
g)(R)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈:在0℃下,向(2R)-2-((2-[3-((5-氰基吡嗪-2-基)氨基)-1H-吡唑-5-基]-3-甲氧基苯氧基)甲基]吗啉-4-甲酸叔丁基酯(12mg,23.64umol)的DCM(2.5mL)溶液中加入TFA(808.77mg,7.09mmol,525.17uL)。所得混合物在20℃下搅拌1h,然后减压浓缩得到粗产物,经制备色谱柱分离纯化得到目标化合物(7.59mg,14.05μmol,白色固体,59.44%收率,TFA盐)。
实施例4化合物由实施例1化合物和MeI在K2CO3存在下在DMF中合成制得。该化合物也可采用本领域技术人员已知的其他方法合成制得。
实施例5-50采用类似于实施例1或2的合成方法制得。
实施例51
(S)-5-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-4-甲基-1H-吡唑-3-基)氨基)吡嗪-2-甲腈
a)(3S)-3-[[2-(3-氨基-4-溴-1H-吡唑-5-基)-3-甲氧基苯氧基]甲基]哌啶-1-羧酸叔丁酯:将(3S)-3-[[2-(3-氨基-1H-吡唑-5-基)-3-甲氧基苯氧基]甲基]哌啶-1-羧酸叔丁酯(1.6g,3.98mmol,采用与实施例1e相似的方法制备)和NBS(778.29mg,4.37mmol)溶于乙腈(32mL)。反应液在25℃下搅拌12h。在0℃下用饱和NaHCO3溶液(150mL)淬灭反应,如何用乙酸乙酯(50mL×3)萃取。合并有机相用饱和食盐水(50mL×3)洗涤、Na2SO4干燥,过滤、减压浓缩得到粗品(1.9g,红色油状物)。MS(ESI,m/z):481.1[M+H]+。
b)(3S)-3-[[2-(3-氨基-4-甲基-1H-吡唑-5-基)-3-甲氧基苯氧基]甲基]哌啶-1-羧酸叔丁酯:将(3S)-3-[[2-(3-氨基-4-溴-1H-吡唑-5-基)-3-甲氧基苯氧基]甲基]哌啶-1-羧酸叔丁酯(500mg,1.04mmol)、甲基硼酸(373.05mg,6.23mmol)、氯(2-二环己基膦基-2',4',6'-三异丙基-1,1'-联苯基)[2-(2'-氨基-1,1'-联苯)]钯(II)(XPhos Pd G2,163.45mg,207.74μmol)、叔丁基-[2-(2,4,6-三异丙基苯基)苯基]膦(176.43mg,415.47μmol)和K2CO3(861.31mg,6.23mmol)溶于二氧六环(50mL)。氮气保护下反应液在100℃下搅拌12h。过滤反应液,减压浓缩得粗品。粗品通过反向HPLC纯化(0.1%甲酸)得到目标化合物和副产物((3S)-3-[[2-(3-氨基-1H-吡唑-5-基)-3-甲氧基-苯氧基]甲基]哌啶-1-羧酸叔丁酯)(180mg,棕色固体)。MS(ESI,m/z):417.2[M+H]+。
c)(3S)-3-[[2-[3-[(5-氰基吡嗪-2-基)氨基]-4-甲基-1H-吡唑-5-基]-3-甲氧基-苯氧基]甲基]哌啶-1-羧酸叔丁基酯:将上述化合物(实施例51b,432.16μmol,180mg)溶于DMSO(5mL),加入5-氯吡嗪-2-甲腈(180.91mg,1.30mmol)和DIPEA(167.56mg,1.30mmol)。反应液在90℃下搅拌16h。反应液加水(30mL)稀释并用乙酸乙酯(30mL×3)萃取,Na2SO4干燥,过滤、减压浓缩得到粗品。粗品通过反向HPLC(0.1%甲酸)和制备HPLC(色谱柱;WelchUltimate XB-CN 250×70×10μm;流动相;[正己烷-乙醇(0.1%氨水)];B%:20%-60%,15分钟)纯化得到目标化合物(50mg,黄色油状物)。MS(ESI,m/z):520.2[M+H]+。
d)(S)-5-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-4-甲基-1H-吡唑-3-基)氨基)吡嗪-2-甲腈:将(3S)-3-[[2-[3-[(5-氰基吡嗪-2-基)氨基]-4-甲基-1H-吡唑-5-基]-3-甲氧基-苯氧基]甲基]哌啶-1-羧酸叔丁基酯(50mg,96.23μmol)溶于DCM(1mL),加入TFA(274.30mg,2.41mmol,178.12μL)。反应液在25℃下搅拌2h。减压浓缩反应液得粗品。粗品通过制备HPLC纯化(色谱柱:Phenomenex luna C18 150×25mm×10μm;流动相:[水(0.225%甲酸)-乙腈];B%:8%-38%,10分钟)得目标产物(24.63mg,黄色固体,收率53.55%)。MS(ESI,m/z):420.2[M+H]+。1H NMR(400MHz,CD3OD):δ8.46(d,J=1.2Hz,1H),8.32(d,J=1.2Hz,1H),7.41(t,J=8.4Hz,1H),6.77(dd,J=8.4Hz,17.6Hz,2H),4.02-3.97(m,1H),3.89-3.85(m,1H),3.79(s,3H),3.27-3.25(m,1H),2.83-2.75(m,1H),2.67(t,J=12.0Hz,1H),2.17-2.08(m,1H),1.89-1.83(m,2H),1.81(s,3H),1.75-1.63(m,1H),1.41-1.29(m,2H)。SFC:ee%:100%。
实施例52
(S)-5-((4-溴-5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈
a)(3S)-3-[[2-[3-[(5-氰基吡嗪-2-基)氨基]-1H-吡唑-5-基]-3-甲氧基-苯氧基]甲基]哌啶-1-羧酸叔丁基酯:将(3S)-3-[[2-(3-氨基-1H-吡唑-5-基)-3-甲氧基-苯氧基]甲基]哌啶-1-羧酸叔丁酯(实施例51c,500mg,1.24mmol)溶于DMSO(5mL),加入DIPEA(481.66mg,3.73mmol,649.13μL)和5-氯吡嗪-2-腈(520.05mg,3.73mmol)。反应液在90℃下搅拌16h。反应液用水(30mL)稀释,并用乙酸乙酯(30mL×3)萃取,Na2SO4干燥,过滤、减压浓缩得到粗品。粗品通过反向HPLC(0.1%甲酸)和制备HPLC(色谱柱:色谱柱:Phenomenexluna C18 150×25mm×10μm;流动相:[水(0.225%甲酸)-乙腈];B%:55%-85%,10分钟)纯化得到目标化合物(330mg,棕色固体,收率52.54%)。MS(ESI,m/z):506.3[M+H]+。
b)(3S)-3-[[2-[4-溴-3-[(5-氰基吡嗪-2-基)氨基]-1H-吡唑-5-基]-3-甲氧基-苯氧基]甲基]哌啶-1-羧酸叔丁基酯:将(3S)-3-[[2-[3-[(5-氰基吡嗪-2-基)氨基]-1H-吡唑-5-基]-3-甲氧基-苯氧基]甲基]哌啶-1-羧酸叔丁基酯(280mg,553.83μmol)溶于乙腈(10mL),加入NBS(108.43mg,609.22μmol)。反应液在25℃下搅拌12h。用NaHCO3溶液(10mL)调节pH至7。混合液用乙酸乙酯(30mL×3)萃取,Na2SO4干燥,过滤、减压浓缩得到粗品。粗品通过反向HPLC(0.1%甲酸)纯化得到目标化合物(138mg,黄色油状,收率36.2%)。MS(ESI,m/z):584.0[M+H]+。
c)(S)-5-((4-溴-5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈:将(3S)-3-[[2-[4-溴-3-[(5-氰基吡嗪-2-基)氨基]-1H-吡唑-5-基]-3-甲氧基-苯氧基]甲基]哌啶-1-羧酸叔丁基酯(138mg,236.11μmol)溶于DCM(2mL),加入TFA(673.06mg,5.90mmol,437.05μL)。反应液在25℃下搅拌2h。减压浓缩反应液得粗品。粗品通过制备HPLC(色谱柱:色谱柱:Phenomenex luna C18 150×25mm×10μm;流动相:[水(0.225%甲酸)-乙腈];B%:10%-43%,11分钟)纯化得到目标化合物(81.54mg,淡黄色固体,收率64.21%)。MS(ESI,m/z):484.0[M+H]+。1H NMR(400MHz,CD3OD):δ8.50(d,J=1.2Hz,1H),8.44(d,J=1.2Hz,1H),7.44(t,J=8.4Hz,1H),6.80-6.74(m,2H),4.04-4.01(m,1H),3.91-3.87(m,1H),3.80(s,3H),3.37-3.34(m,2H),2.84-2.80(m,1H),2.75-2.69(m,1H),2.17-2.16(m,1H),1.94-1.86(m,2H),1.75-1.66(m,1H),1.40-1.39(m,1H)。SFC:ee%:100%。
实施例53-75采用类似于实施例1或2的合成方法制得。该化合物也可采用本领域技术人员已知的其他方法合成制得。
实施例76
(S)-5-((5-(2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈和(R)-5-((5-(2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈
a)2-[[2-[3-[(5-氰基吡嗪-2-基)氨基]-1H-吡唑-5-基]-3-甲氧基苯氧基]甲基]硫代吗啉-4-羧酸叔丁酯:将[[5-(2-羟基-6-甲氧基-苯基)-1H-吡唑-3-基]氨基]吡嗪-2-甲腈(实施例3e,300mg,973.10μmol)、2-(羟甲基)硫代吗啉-4-羧酸叔丁酯(340.57mg,1.46mmol)和2-(三丁基亚膦基)乙腈(704.57mg,2.92mmol)溶于甲苯(16mL)。反应液在90℃下搅拌4h。减压浓缩反应液得粗品。粗品通过制备HPLC纯化得目标化合物粗品(83mg,黄色油状,收率16.3%)。MS(ESI,m/z):524.3[M+H]+。
b)5-[[5-[2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基]-1H-吡唑-3-基]氨基]吡嗪-2-甲腈:将2-[[2-[3-[(5-氰基吡嗪-2-基)氨基]-1H-吡唑-5-基]-3-甲氧基苯氧基]甲基]硫代吗啉-4-羧酸叔丁酯(81mg,154.70μmol)溶于HCOOH(1mL),反应体系氮气置换3次,反应液在氮气保护下25℃搅拌1h。减压浓缩反应液得粗品。粗品通过制备HPLC(色谱柱:色谱柱:Phenomenex luna C18 150×25mm×10μm;流动相:[水(0.225%甲酸)-乙腈];B%:9%-39%,10分钟)纯化得到目标化合物粗品(65mg,黄色固体,收率99.2%)。MS(ESI,m/z):524.3[M+H]+。1H NMR(400MHz,DMSO-d6):δ8.47(s,2H),6.99-6.90(m,1H),6.61(d,J=10.4Hz,2H),4.15-4.09(m,2H),3.89(s,3H),3.69-3.64(m,2H),3.13(s,1H),2.85-2.71(m,1H),2.54-2.52(m,1H),1.82-1.81(m,1H),1.62-1.54(m,2H)。
c)(S)-5-((5-(2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈和(R)-5-((5-(2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈:将上述产物通过SFC分离纯化(色谱柱:DAICEL CHIRALPAK IG(250mm×30mm,10μm);流动相:[0.1%氨水甲醇];B%:70%-70%,6.2;60min)得到2个粗品。粗品1通过制备HPLC纯化(色谱柱:Unisil 3-100 C18 Ultra 150×50mm×3μm;流动相:[水(0.225%甲酸)-乙腈];B%:15%-35%,10min)得到一个目标产物(76-A,17.42mg,淡黄色固体,收率25.74%)。粗品2通过制备HPLC纯化(色谱柱:Unisil 3-100C18 Ultra 150×50mm×3μm;流动相:[水(0.225%甲酸)-乙腈];B%:15%-35%,10min)得到另一个目标产物(76-B,12.15mg,淡黄色固体,收率17.91%)。
实施例77-80使用与实施例1或2类似的合成方法制备及并使用与实施例76类似的方法分离。这些化合物也可采用本领域技术人员已知的其他方法合成制得。
实施例81
测定本发明化合物对CHK1激酶的抑制作用
CHK1酶活性的检测是采用Promega的ADP-GloTM kinase assay试剂盒(#V9101),在384孔板(Corning,#4512)中进行。在384板中先后加入2μL激酶CHK1(#V1941,Promega)、1μL用缓冲液稀释的化合物、2μL的ATP底物(最终浓度CHK1是1ng/孔,ATP是10μM),阳性对照为DMSO加酶和底物孔,阴性对照为DMSO不加酶和加底物孔,1000rpm转速离心1分钟,室温下避光反应1小时。然后每孔加入5μL的ADP-Glo试剂,室温反应40分钟后,每孔加入10μL的激酶检测试剂,在 Flash(Thermo)仪器上检测相对化学发光值(RLU)。计算抑制率%=(阳性对照的RLU–化合物的RLU)/(阳性对照的RLU–阴性对照的RLU)×100,使用软件GraphPad Prism6.0分析数据,以曲线方程:Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))进行拟合,计算IC50值。
表1汇总了化合物在10nM/100nM浓度下对CHK1激酶活性的抑制效应(抑制率%)。
表1
表2汇总了化合物的CHK1激酶活性的抑制效应(IC50)。
表2
实施例 | 1 | 9 | 12 | 13 | 14 | 28 | 31 |
IC<sub>50</sub>(nM) | 0.84 | 0.97 | 0.72 | 0.45 | 0.69 | 0.3 | 0.38 |
实施例 | 35 | 37 | 38 | 39 | 40 | 41 | 43 |
IC<sub>50</sub>(nM) | 1.78 | 0.77 | 0.52 | 0.2 | 0.88 | 0.85 | 1.17 |
实施例 | 44 | 45 | 46 | 48 | 54 | 56 | 59 |
IC<sub>50</sub>(nM) | 0.93 | 1.57 | 0.59 | 0.58 | 0.86 | 1.02 | 2.27 |
实施例 | 62 | 63 | 65 | 66 | 67 | 68 | 70 |
IC<sub>50</sub>(nM) | 1.58 | 1.66 | 0.26 | 1.22 | 1.72 | 0.44 | 1.16 |
实施例 | 76-A | 76-B | LY2606368 | ||||
IC<sub>50</sub>(nM) | 0.79 | 1.21 | 1.34 |
因此,经CHK1激酶实验测定,本发明化合物(实施例1)及其类似物对CHK1激酶有好的抑制效应。
实施例82
应用MTT检测法测定本发明化合物对人乳腺癌细胞HCC1806增长的抑制作用
将新复苏的细胞培养传代至第三代后,且生长状态良好、融合度90%左右,开始用于实验。用胰酶消化细胞,800rpm离心5min,弃上清,用新鲜培基重悬,并计数,以2000细胞/孔的密度接种至96孔细胞培养板,置于37℃5%CO2培养箱培养过夜。受试物(包括待测化合物和参考化合物)母液用DMSO按1:3比例分别进行连续系列稀释至8个浓度。每个浓度取5μL加入到120μL培基(25倍稀释),振荡混匀。取培养过夜的细胞,除去培养基,每孔加入195μL新鲜培基,再分别加入5μL稀释好的含相应浓度受试物的培基,随后将培养板置于37℃5%CO2培养箱培养3天。除去原液,每孔加100μL含MTT(0.5mg/mL)的新鲜无血清培基后,继续培养。4h后除去原液,每孔加入100μL DMSO,避光震荡10min,置于多功能读数仪读取552/690nm波长的吸光值(OD值)。
用软件GraphPad Prism 6.0分析数据,化合物对细胞增殖的抑制活性以细胞存活率对化合物浓度对数为坐标绘图。细胞存活率%=(OD化合物-OD背景)/(ODDMSO-OD背景)×100。IC50值以S形剂量反应曲线方程拟合,曲线方程为:Y=100/(1+10^(LogC-LogIC50)),C是化合物浓度。
表3汇总了化合物对人乳腺癌细胞HCC1806增长的抑制作用数据(IC50)。
表3
因此,经MTT检测法测定,本发明化合物(实施例1)及其类似物对HCC1806细胞增长有好的抑制作用。
实施例83
应用MTT检测法测定本发明化合物对人胰腺癌细胞SW1990增长的抑制作用
将新复苏的细胞培养传代至第三代后,且生长状态良好、融合度90%左右,开始用于实验。用胰酶消化细胞,800rpm离心5min,弃上清,用新鲜培基重悬,并计数,以5000细胞/孔的密度接种至96孔细胞培养板,置于37℃5%CO2培养箱培养过夜。受试物(包括待测化合物和参考化合物)母液用DMSO按1:3比例分别进行连续系列稀释至8个浓度。每个浓度取5μL加入到120μL培基(25倍稀释),振荡混匀。取培养过夜的细胞,除去培养基,每孔加入195μL新鲜培基,再分别加入5μL稀释好的含相应浓度受试物的培基,随后将培养板置于37℃5%CO2培养箱培养5天。除去原液,每孔加100μL含MTT(0.5mg/mL)的新鲜无血清培基后,继续培养。4h后除去原液,每孔加入100μL DMSO,避光震荡10min,置于多功能读数仪读取552/690nm波长的吸光值(OD值)。
用软件GraphPad Prism 6.0分析数据,化合物对细胞增殖的抑制活性以细胞存活率对化合物浓度对数为坐标绘图。细胞存活率%=(OD化合物-OD背景)/(ODDMSO-OD背景)×100。IC50值以S形剂量反应曲线方程拟合,曲线方程为:Y=100/(1+10^(LogC-LogIC50)),C是化合物浓度。
表4汇总了化合物对人胰腺癌细胞SW1990增长的抑制作用数据(IC50)。
表4
因此,经MTT检测法测定,本发明化合物(实施例1)及其类似物对SW1990细胞增长有好的抑制作用。
实施例84
应用MTT检测法测定本发明化合物对人结肠癌细胞LoVo增长的抑制作用
将新复苏的细胞培养传代至生长状态良好、融合度90%左右,开始用于实验。用胰酶消化细胞,800rpm离心5min,弃上清,用新鲜培基重悬,并计数,以5000细胞/孔的密度接种至96孔细胞培养板,置于37℃5%CO2培养箱培养过夜。受试物(包括待测化合物和参考化合物)母液用DMSO按1:3比例分别进行连续系列稀释至8个浓度。每个浓度取5μL加入到120μL培基(25倍稀释),振荡混匀。取培养过夜的细胞,除去培养基,每孔加入195μL新鲜培基,再分别加入5μL稀释好的含相应浓度受试物的培基,随后将培养板置于37℃5%CO2培养箱培养4天。除去原液,每孔加100μL含MTT(0.5mg/mL)的新鲜无血清DMEM培基后,继续培养。4h后除去原液,每孔加入100μL DMSO,避光震荡10min,置于多功能读数仪读取552/690nm波长的吸光值(OD值)。
用软件GraphPad Prism 6.0分析数据,化合物对细胞增殖的抑制活性以细胞存活率对化合物浓度对数为坐标绘图。细胞存活率%=(OD化合物-OD背景)/(ODDMSO-OD背景)×100。IC50值以S形剂量反应曲线方程拟合,曲线方程为:Y=100/(1+10^(LogC-LogIC50)),C是化合物浓度。
表5汇总了化合物对人结肠癌细胞LoVo增长的抑制作用数据(IC50)。
表5
因此,经MTT检测法测定,本发明化合物(实施例1)及其类似物对LoVo细胞增长有好的抑制作用。
虽然已经充分地描述了本发明,但是本领域技术人员应当理解,可在不影响本发明范围或其任何实施方案的情况下,在广泛且等同的条件、制剂和其它参数范围内进行相同实施。本文所引用的所有专利、专利申请和出版物都全文引入本文以供参考。
Claims (15)
1.式I的化合物,或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药:
其中,
A0、A1和A2各自独立选自N和CRa;
R0选自氢、氰基、烷基、烷氧基或羰基,其中烷基、烷氧基或羰基可被任选取代;
R1选自卤素、羟基或可被任选取代的烷氧基;
R2-R4各自独立为氢、卤素、烷基、烷氧基、硝基、羰基或酰氨基,其中烷基、烷氧基、羰基或酰氨基可被任选取代;
R5选自氢、可被任选取代的烷基或可被任选取代的烷氧基;
R6选自氢、卤素或可被任选取代的烷基;
L是键、-C(Rb)2-、O、S或NRb;
Z是键或亚烷基;
Q是可被任选取代的杂环基;
Ra选自H、可被任选取代的烷基和卤素;
Rb各自独立为氢或可被任选取代的烷基。
2.权利要求1的化合物,其中,
A0和A1是N或CH;A2是N、CH或CCH3;
R0是氰基、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基;
R1是卤素、羟基、C1-C3烷氧基或卤代C1-C3烷氧基;
R2-R4各自独立为氢、卤素、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基;
R5是氢;
R6是氢;
L是C1-C3亚烷基、O、S或NRb,优选的Rb是氢或C1-C3烷基;
Z为C1-C3亚烷基,更优选为亚甲基;
Q为无取代的饱和的3-7元杂环基,或被1-2个任选取代的C1-C3烷基取代的饱和3-7元杂环基,其中,所述取代基位于连接位的邻位、间位和/或对位,而不位于连接位置。
3.权利要求1的化合物,其为式IIa的化合物,或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药:
其中,R0是氰基、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基;
R1是卤素、羟基、C1-C3烷氧基或卤代C1-C3烷氧基;
R2-R4各自独立为氢、卤素、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基;
L是C1-C3亚烷基、O、S或NRb,其中Rb是氢或C1-C3烷基;
Z是键或亚烷基;
Q是无取代的杂环基或可被任选取代的杂环基,其中,所述取代基位于连接位的邻位、间位和/或对位,而不位于连接位置;优选地,Q为无取代的饱和的3-7元杂环基,或被1-2个任选取代的C1-C3烷基取代的饱和3-7元杂环基;优选的Q包括如下基团:
其中,*表示所述基团与化合物剩余部分的连接位置。
4.权利要求1的化合物,其为式IIb的化合物,或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或前药:
其中,R0是氰基、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基;
R1是卤素、羟基、C1-C3烷氧基或卤代C1-C3烷氧基;
R2-R4各自独立为氢、卤素、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基;
L是C1-C3亚烷基、O、S或NRb,其中Rb是氢或C1-C3烷基;
Q为无取代的饱和的3-7元杂环基,或被1-2个任选取代的C1-C3烷基取代的饱和3-7元杂环基,其中,所述取代基位于连接位的邻位、间位和/或对位,而不位于连接位置;优选的Q选自:
其中,*表示所述基团与化合物剩余部分的连接位置。
7.权利要求6的化合物,其中:
A0和A1是N或CH;A2是N、CH或CCH3;
R0是氰基、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基;
R1是卤素、羟基、C1-C3烷氧基或卤代C1-C3烷氧基;
R2-R4各自独立为氢、卤素、C1-C3烷基、C1-C3烷氧基或卤代C1-C3烷基;
R5是氢;
R6是氢;
L是C1-C3亚烷基、O、S或NRb,优选的Rb是氢或C1-C3烷基;
Z为C1-C3亚烷基,更优选为亚甲基;
Q是无取代的饱和3-7元杂环基;优选哌啶基、哌嗪基、吡咯烷基、吗啉基、硫代吗啉基、四氢吡喃基和杂氮环丁烷基;
R7是C1-C3烷基;
n是0-2。
8.权利要求6的化合物,其中:
A0是N;
A1是N;
A2是CH;
A3是CH;
R0是氰基;
R1是卤素、羟基或C1-C3烷氧基;
R2是氢;
R3是氢、卤素、C1-C3烷基或卤代C1-C3烷基;
R4是氢;
R5是氢;
R6是氢;
L是O;
Z为C1-C3亚烷基,更优选为亚甲基;
环Q是无取代的饱和3-7元杂环基,优选哌啶基、哌嗪基、吡咯烷基、吗啉基、硫代吗啉基、四氢吡喃基和杂氮环丁烷基;
n是0。
9.权利要求1的化合物,其中所述化合物选自:
(S)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)氰基吡啶;
(R)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-((4-甲基吗啉-2-基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-N-(5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)-5-(三氟甲基)吡嗪-2-胺;
(S)-N-(5-(2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)-5-甲基吡嗪-2-胺;
(R)-5-((5-(2-甲氧基-6-(吗啉-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-((四氢-2H-吡喃-2-基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-(哌嗪-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-((1-甲基哌嗪-2-基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
5-((5-(2-甲氧基-6-(哌啶-4-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-(吡咯烷-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-氟-2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(3-氯-2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-氯-2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(3-氯-6-甲氧基-2-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-溴-2-甲氧基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-(吗啉-2-基甲氧基)-4-(三氟甲基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-(吗啉-2-基甲氧基)-6-(三氟甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-((吗啉-2-基甲基)氨基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-(甲基(吗啉-2-基甲基)氨基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
5-((5-(2-甲氧基-6-(2-(哌嗪-1-基)乙基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-6-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)烟腈;
(S)-6-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)哒嗪-3-甲腈;
(S)-5-甲氧基-N-(5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)吡嗪-2-胺;
(S)-5-乙基-N-(5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)吡嗪-2-胺;
(S)-5-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)-3-甲基吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)-6-甲基吡嗪-2-甲腈;
5-((5-(2-甲氧基-6-(哌啶-4-基氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
5-((5-(2-(杂氮环丁烷-3-基甲氧基)-6-甲氧基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-((1-甲基哌啶-3-基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(R)-5-((5-(2-甲氧基-6-(哌啶-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-((四氢-2H-吡喃-3-基)甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-乙氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-异丙氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(3-氟-2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-氟-2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-氟-2-甲氧基-6-(四氢吡咯-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-氯-2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-溴-2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-3-甲基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-4-甲基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-4-甲基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)-4-(三氟甲基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-氟-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-氯-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-羟基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-((4,4-二甲基哌啶-3-基)甲氧基)-6-甲氧基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-((4,4-二甲基哌啶-3-基)甲氧基)-4-氟-6-甲氧基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-4-甲基-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((4-溴-5-(2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
5-((5-(2-(氮杂环丁烷-3-基甲氧基)-6-氟苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-氟-6-(吡咯烷-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-氟-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2,4-二氟-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-氯-2-氟-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-氯-2-氟-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-溴-2-氟-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-溴-2-氟-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
5-((5-(2-(氮杂环丁烷-3-基甲氧基)-6-氟-4-甲基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-氟-4-甲基-6-(吡咯烷-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-氟-4-甲基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-氟-4-甲基-6-(吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(R)-5-((5-(2-甲氧基-6-(吡咯烷-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(R)-5-((5-(4-氟-2-甲氧基-6-(吡咯烷-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
5-((5-(2-(氮杂环丁烷-3-基甲氧基)-4-氯-6-甲氧基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-氯-2-甲氧基-6-(吡咯烷-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
5-((5-(2-(氮杂环丁烷-3-基甲氧基)-4-溴-6-甲氧基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-溴-2-甲氧基-6-(吡咯烷-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(R)-5-((5-(4-溴-2-甲氧基-6-(吡咯烷-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
5-((5-(2-(氮杂环丁烷-3-基甲氧基)-6-甲氧基-4-甲基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-4-甲基-6-(吡咯烷-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(R)-5-((5-(2-甲氧基-4-甲基-6-(吡咯烷-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-乙基-2-甲氧基-6-(哌啶-3-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈和(R)-5-((5-(2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-氟-2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈和(R)-5-((5-(4-氟-2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-氯-2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈和(R)-5-((5-(4-氯-2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(4-溴-2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈和(R)-5-((5-(4-溴-2-甲氧基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
(S)-5-((5-(2-甲氧基-4-甲基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈和(R)-5-((5-(2-甲氧基-4-甲基-6-(硫代吗啉-2-基甲氧基)苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈;
或其医药上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、溶剂化物、水合物或其前药。
10.权利要求1~9中任一项所述的化合物在制备治疗或预防CHK1持续性活化或DNA复制期间的高内在DNA损害或损伤相关的疾病、障碍和病症的药物中的用途;优选地,所述疾病、障碍和病症是癌症。
11.权利要求10的用途,其中所述癌症选自肝癌、黑素瘤、霍奇金病、非霍奇金淋巴瘤、急性淋巴白血病、慢性淋巴白血病、多发性骨髓瘤、成神经细胞瘤、乳腺癌、卵巢癌、肺癌、维尔姆斯瘤、子宫颈癌、睾丸癌、软组织肉瘤、原发性巨球蛋白血症、膀胱癌、慢性粒细胞白血病、原发性脑癌、恶性黑素瘤、小细胞肺癌、胃癌、结肠癌、恶性胰腺胰岛瘤、恶性类癌性癌症、绒毛膜癌、蕈樣肉芽腫、头颈癌、骨原性肉瘤、胰腺癌、急性粒细胞白血病、毛细胞白血病、横纹肌肉瘤、卡波西肉瘤、泌尿生殖系统肿瘤病、甲状腺癌、食管癌、恶性高钙血症、子宫颈增生症、肾细胞癌、子宫内膜癌、真性红细胞增多症、特发性血小板增多症、肾上腺皮质癌、皮肤癌和前列腺癌。
12.权利要求11的用途,其中所述药物还包括至少一种已知的抗癌药物,或所述抗癌药物的可药用盐;优选地,所述抗癌药物选自下组中的一种或多种:白消安、马法兰、苯丁酸氮芥、环磷酰胺、异环磷酰胺、替莫唑胺、苯达莫司汀、顺铂、丝裂霉素C、博莱霉素、卡铂、喜树碱、伊立替康、托泊替康、阿霉素、表阿霉素、阿克拉霉素、米托蒽醌、甲基羟基玫瑰树碱、铭托泊普、5-氮杂胞苷、吉西他滨、5-氟尿嘧啶、甲氨蝶呤、5-氟-2'-去氧尿苷、氟达拉滨、奈拉滨、阿糖胞苷、普拉曲沙、培美曲塞、羟基脲、硫代鸟嘌呤、秋水仙碱、长春碱、长春新碱、长春瑞滨、紫杉醇、伊沙匹隆、卡巴他赛、多西他赛、单抗、帕尼单抗、耐措妥珠单抗、纳武单抗、派姆单抗、雷莫芦单抗、贝伐珠单抗、帕妥珠单抗、曲妥珠单抗、西妥昔单抗、奥滨尤妥珠单抗、奥法木单抗、利妥昔单抗、阿仑单抗、替伊莫单抗、托西莫单抗、本妥昔单抗、达雷木单抗、埃罗妥珠单抗、T-DM1、Ofatumumab、Dinutuximab、Blinatumomab、易普利姆玛、阿瓦斯丁、赫赛汀、美罗华、伊马替尼、吉非替尼、厄洛替尼、奥斯替尼、阿法替尼、赛立替尼、艾乐替尼、克唑替尼、埃罗替尼、拉帕替尼、索拉非尼、舒尼替尼、尼罗替尼、达沙替尼、帕唑帕尼、特癌适、依维莫司、伏立诺他、罗咪地辛、帕比司他、贝利司他、他莫昔芬、来曲唑、氟维司群、米托胍腙、奥曲肽、视黄酸、砒霜、唑来膦酸、硼替佐米、卡非佐米、Ixazomib、维莫德吉、索尼德吉、狄诺塞麦、萨力多胺、来那度胺、Venetoclax、Aldesleukin(重组人白介素-2)、Sipueucel-T(前列腺癌治疗疫苗)、帕博西尼、奥拉帕尼、Niraparib,Rucaparib、Talazoparib和Senaparib。
13.权利要求10的用途,其中所述药物与放射治疗联用。
14.一种药用组合物,包括权利要求1~9中任一项所述的化合物与可药用载体。
15.权利要求14的药用组合物,其中所述药用组合物还含有至少一种已知的抗癌药物,或所述抗癌药物的可药用盐;优选地,所述至少一种已知的抗癌药物选自下组:白消安、马法兰、苯丁酸氮芥、环磷酰胺、异环磷酰胺、替莫唑胺、苯达莫司汀、顺铂、丝裂霉素C、博莱霉素、卡铂、喜树碱、伊立替康、托泊替康、阿霉素、表阿霉素、阿克拉霉素、米托蒽醌、甲基羟基玫瑰树碱、铭托泊普、5-氮杂胞苷、吉西他滨、5-氟尿嘧啶、甲氨蝶呤、5-氟-2'-去氧尿苷、氟达拉滨、奈拉滨、阿糖胞苷、普拉曲沙、培美曲塞、羟基脲、硫代鸟嘌呤、秋水仙碱、长春碱、长春新碱、长春瑞滨、紫杉醇、伊沙匹隆、卡巴他赛、多西他赛、单抗、帕尼单抗、耐措妥珠单抗、纳武单抗、派姆单抗、雷莫芦单抗、贝伐珠单抗、帕妥珠单抗、曲妥珠单抗、西妥昔单抗、奥滨尤妥珠单抗、奥法木单抗、利妥昔单抗、阿仑单抗、替伊莫单抗、托西莫单抗、本妥昔单抗、达雷木单抗、埃罗妥珠单抗、T-DM1、Ofatumumab、Dinutuximab、Blinatumomab、易普利姆玛、阿瓦斯丁、赫赛汀、美罗华、伊马替尼、吉非替尼、厄洛替尼、奥斯替尼、阿法替尼、赛立替尼、艾乐替尼、克唑替尼、埃罗替尼、拉帕替尼、索拉非尼、舒尼替尼、尼罗替尼、达沙替尼、帕唑帕尼、特癌适、依维莫司、伏立诺他、罗咪地辛、帕比司他、贝利司他、他莫昔芬、来曲唑、氟维司群、米托胍腙、奥曲肽、视黄酸、砒霜、唑来膦酸、硼替佐米、卡非佐米、Ixazomib、维莫德吉、索尼德吉、狄诺塞麦、萨力多胺、来那度胺、Venetoclax、Aldesleukin(重组人白介素-2)、Sipueucel-T(前列腺癌治疗疫苗)、帕博西尼、奥拉帕尼、Niraparib,Rucaparib、Talazoparib和Senaparib。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910845684 | 2019-09-06 | ||
CN2019108456848 | 2019-09-06 | ||
CN2020101550019 | 2020-03-06 | ||
CN202010155001.9A CN112457306A (zh) | 2019-09-06 | 2020-03-06 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
PCT/CN2020/113233 WO2021043208A1 (en) | 2019-09-06 | 2020-09-03 | 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114728945A true CN114728945A (zh) | 2022-07-08 |
CN114728945B CN114728945B (zh) | 2024-01-16 |
Family
ID=74832781
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010155001.9A Withdrawn CN112457306A (zh) | 2019-09-06 | 2020-03-06 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
CN202080062058.2A Active CN114728945B (zh) | 2019-09-06 | 2020-09-03 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010155001.9A Withdrawn CN112457306A (zh) | 2019-09-06 | 2020-03-06 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220356181A1 (zh) |
EP (1) | EP4028393A4 (zh) |
JP (1) | JP2022547294A (zh) |
KR (1) | KR20220059496A (zh) |
CN (2) | CN112457306A (zh) |
AU (1) | AU2020342189A1 (zh) |
CA (1) | CA3149891A1 (zh) |
WO (1) | WO2021043208A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2024520481A (ja) * | 2021-05-27 | 2024-05-24 | バウンドレス バイオ,インク. | チェックポイントキナーゼ1(chk1)阻害剤およびその使用 |
TW202333680A (zh) * | 2021-12-24 | 2023-09-01 | 日商住友製藥股份有限公司 | 具有二環性骨架之1h-吡唑-3-胺衍生物 |
WO2023226658A1 (en) * | 2022-05-25 | 2023-11-30 | Sperogenix Therapeutics Limited | Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof |
GB202213792D0 (en) | 2022-09-21 | 2022-11-02 | Benevolentai Bio Ltd | New compounds and method |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004052280A2 (en) * | 2002-12-10 | 2004-06-24 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
CN101321760A (zh) * | 2005-10-06 | 2008-12-10 | 先灵公司 | 作为蛋白激酶抑制剂的吡唑并嘧啶 |
US20090048301A1 (en) * | 2003-07-09 | 2009-02-19 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
CN106170288A (zh) * | 2014-02-10 | 2016-11-30 | 卡斯卡迪安疗法公司 | 药物化合物 |
CN108601781A (zh) * | 2016-02-04 | 2018-09-28 | 广州必贝特医药技术有限公司 | 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用 |
CN110167941A (zh) * | 2017-01-09 | 2019-08-23 | 上海瑛派药业有限公司 | 取代的稠合杂芳基化合物作为激酶抑制剂及其应用 |
-
2020
- 2020-03-06 CN CN202010155001.9A patent/CN112457306A/zh not_active Withdrawn
- 2020-09-03 CA CA3149891A patent/CA3149891A1/en active Pending
- 2020-09-03 US US17/640,564 patent/US20220356181A1/en active Pending
- 2020-09-03 EP EP20859909.2A patent/EP4028393A4/en active Pending
- 2020-09-03 AU AU2020342189A patent/AU2020342189A1/en active Pending
- 2020-09-03 CN CN202080062058.2A patent/CN114728945B/zh active Active
- 2020-09-03 WO PCT/CN2020/113233 patent/WO2021043208A1/en unknown
- 2020-09-03 JP JP2022514802A patent/JP2022547294A/ja active Pending
- 2020-09-03 KR KR1020227010561A patent/KR20220059496A/ko unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004052280A2 (en) * | 2002-12-10 | 2004-06-24 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
US20090048301A1 (en) * | 2003-07-09 | 2009-02-19 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
CN101321760A (zh) * | 2005-10-06 | 2008-12-10 | 先灵公司 | 作为蛋白激酶抑制剂的吡唑并嘧啶 |
CN106170288A (zh) * | 2014-02-10 | 2016-11-30 | 卡斯卡迪安疗法公司 | 药物化合物 |
CN108601781A (zh) * | 2016-02-04 | 2018-09-28 | 广州必贝特医药技术有限公司 | 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用 |
CN110167941A (zh) * | 2017-01-09 | 2019-08-23 | 上海瑛派药业有限公司 | 取代的稠合杂芳基化合物作为激酶抑制剂及其应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2022547294A (ja) | 2022-11-11 |
WO2021043208A1 (en) | 2021-03-11 |
CN112457306A (zh) | 2021-03-09 |
AU2020342189A1 (en) | 2022-03-31 |
CN114728945B (zh) | 2024-01-16 |
CA3149891A1 (en) | 2021-03-11 |
KR20220059496A (ko) | 2022-05-10 |
US20220356181A1 (en) | 2022-11-10 |
EP4028393A4 (en) | 2023-08-30 |
EP4028393A1 (en) | 2022-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7012534B2 (ja) | 癌および自己免疫疾患を治療するための最適化された組合せ療法およびその使用 | |
RU2749437C2 (ru) | Ингибиторы протеинкиназ, их способ получения и медицинское применение | |
JP6404717B2 (ja) | アミドスピロ環状アミド及びスルホンアミド誘導体 | |
JP7158286B2 (ja) | PI3Kβ阻害剤としてのアザベンゾイミダゾール誘導体 | |
JP7240784B2 (ja) | 8,9-ジヒドロイミダゾール[1,2-a]ピリミド[5,4-e]ピリミジン-5(6H)-ケトン類化合物 | |
CN114728945B (zh) | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 | |
DK2947086T3 (en) | UNKNOWN CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | |
CN110914277B (zh) | 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用 | |
WO2014164767A1 (en) | Novel compounds and compositions for inhibition of fasn | |
CN114423756A (zh) | 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用 | |
JP7247092B2 (ja) | キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途 | |
CN114502559B (zh) | 二氢咪唑并嘧啶并嘧啶酮类化合物 | |
CN114026097B (zh) | 取代的吡唑并喹唑啉酮化合物及其应用 | |
CN114787162A (zh) | 取代的咪唑并喹喔啉化合物及其应用 | |
CN112480120A (zh) | 取代的咪唑并喹喔啉化合物及其应用 | |
CN116670134A (zh) | 取代的咪唑并[1,5-b]哒嗪化合物作为激酶抑制剂及其应用 | |
CN117820305A (zh) | 杂环取代喹唑啉及其制备方法和应用 | |
BR112019020309A2 (pt) | derivados de quinoxalina e piridopirazina como inibidores de pi3k-beta |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |